IONIS PHARMACEUTICALS INC - Quarter Report: 2023 September (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 10-Q
(Mark One)
| ☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the Quarterly Period Ended September 30, 2023
OR
| ☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from _____ to _____
Commission file number 000-19125
Ionis Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware
|
33-0336973
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification No.)
|
|
2855 Gazelle Court, Carlsbad, California
|
92010
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
760-931-9200
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
Common Stock, $.001 Par Value
|
“IONS”
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,
smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large Accelerated Filer ☒
|
Accelerated Filer ☐
|
|
Non-accelerated Filer ☐
|
Smaller Reporting Company ☐
|
|
Emerging Growth Company ☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Securities Exchange
Act of 1934). Yes ☐ No ☒
The number of shares of voting common stock outstanding as of October 27, 2023 was 143,472,119.
FORM 10-Q
INDEX
|
PART I
|
FINANCIAL INFORMATION
|
|
|
ITEM 1:
|
Financial Statements:
|
|
|
3
|
||
|
Condensed Consolidated
Statements of Operations for the three and nine months ended September 30, 2023 and 2022 (unaudited)
|
4
|
|
|
Condensed Consolidated
Statements of Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 (unaudited)
|
5
|
|
|
Condensed Consolidated Statements of
Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022 (unaudited)
|
6
|
|
|
Condensed Consolidated Statements of
Cash Flows for the nine months ended September 30, 2023 and 2022 (unaudited)
|
8
|
|
|
9
|
||
|
ITEM 2:
|
||
|
22
|
||
|
24
|
||
|
24
|
||
|
31
|
||
|
ITEM 3:
|
33
|
|
|
ITEM 4:
|
33
|
|
|
PART II
|
33
|
|
|
ITEM 1:
|
33
|
|
|
ITEM 1A:
|
33
|
|
|
ITEM 2:
|
51
|
|
|
ITEM 3:
|
51
|
|
|
ITEM 4:
|
51
|
|
|
ITEM 5:
|
51
|
|
|
ITEM 6:
|
52
|
|
|
53
|
||
TRADEMARKS
“Ionis,” the Ionis
logo, and other trademarks or service marks of Ionis Pharmaceuticals, Inc. appearing in this report are the property of Ionis Pharmaceuticals, Inc. “Akcea,” the Akcea logo, and other trademarks or service marks of Akcea Therapeutics, Inc. appearing in
this report are the property of Akcea Therapeutics, Inc., Ionis’ wholly owned subsidiary. This report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience,
trademarks and trade names referred to in this report may appear without the ® or TM symbols.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
|
September 30,
2023
|
December 31,
2022
|
|||||||
|
(unaudited)
|
||||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
352,060
|
$
|
276,472
|
||||
|
Short-term investments
|
1,883,522
|
1,710,397
|
||||||
|
Contracts receivable
|
142,359
|
25,538
|
||||||
|
Inventories
|
25,634
|
22,033
|
||||||
|
Other current assets
|
181,075
|
168,254
|
||||||
|
Total current assets
|
2,584,650
|
2,202,694
|
||||||
|
Property, plant and equipment, net
|
70,928
|
74,294
|
||||||
|
Right-of-use assets
|
174,310
|
181,544
|
||||||
|
Deposits and other assets
|
104,083
|
75,344
|
||||||
|
Total assets
|
$
|
2,933,971
|
$
|
2,533,876
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
5,615
|
$
|
17,921
|
||||
|
Accrued compensation
|
33,781
|
49,178
|
||||||
|
Accrued liabilities
|
118,968
|
140,101
|
||||||
|
Income taxes payable
|
31,070
|
6,249
|
||||||
|
Current portion of deferred contract revenue
|
204,824
|
90,577
|
||||||
|
Other current liabilities
|
9,952
|
7,535
|
||||||
|
Total current liabilities
|
404,210
|
311,561
|
||||||
|
Long-term deferred contract revenue
|
249,272
|
287,768
|
||||||
|
1.75 percent convertible senior notes, net
|
561,609
|
—
|
||||||
|
0 percent convertible senior notes, net
|
624,594
|
622,242
|
||||||
|
0.125 percent convertible senior notes, net
|
44,287
|
544,504
|
||||||
|
Liability related to sale of future royalties, net
|
512,700
|
—
|
||||||
|
Long-term lease liabilities
|
173,038
|
178,941
|
||||||
|
Long-term obligations
|
48,801
|
15,973
|
||||||
|
Total liabilities
|
2,618,511
|
1,960,989
|
||||||
|
Stockholders’ equity:
|
||||||||
|
Common stock, $0.001 par value; 300,000,000 shares authorized, 143,393,493 and 142,057,736
shares issued and outstanding at September 30, 2023 (unaudited) and December 31, 2022, respectively
|
143
|
142
|
||||||
|
Additional paid-in capital
|
2,148,002
|
2,059,850
|
||||||
|
Accumulated other comprehensive loss
|
(46,037
|
)
|
(57,480
|
)
|
||||
|
Accumulated deficit
|
(1,786,648
|
)
|
(1,429,625
|
)
|
||||
|
Total stockholders’ equity
|
315,460
|
572,887
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
2,933,971
|
$
|
2,533,876
|
||||
See accompanying notes.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except for per share amounts)
(Unaudited)
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Revenue:
|
||||||||||||||||
|
Commercial revenue:
|
||||||||||||||||
|
SPINRAZA royalties
|
$
|
67,253
|
$
|
61,647
|
$
|
178,511
|
$
|
175,092
|
||||||||
|
Other commercial revenue
|
16,828
|
10,763
|
51,235
|
47,787
|
||||||||||||
|
Total commercial revenue
|
84,081
|
72,410
|
229,746
|
222,879
|
||||||||||||
|
Research and development revenue:
|
||||||||||||||||
|
Collaborative agreement revenue
|
44,167
|
69,250
|
173,513
|
157,282
|
||||||||||||
|
Eplontersen joint development revenue
|
15,959
|
18,107
|
59,883
|
55,317
|
||||||||||||
|
Total research and development revenue
|
60,126
|
87,357
|
233,396
|
212,599
|
||||||||||||
|
Total revenue
|
144,207
|
159,767
|
463,142
|
435,478
|
||||||||||||
|
Expenses:
|
||||||||||||||||
|
Cost of sales
|
2,191
|
1,515
|
6,071
|
10,430
|
||||||||||||
|
Research, development and patent
|
215,330
|
182,990
|
643,070
|
524,875
|
||||||||||||
|
Selling, general and administrative
|
69,951
|
34,416
|
161,608
|
102,345
|
||||||||||||
|
Total operating expenses
|
287,472
|
218,921
|
810,749
|
637,650
|
||||||||||||
|
Loss from operations
|
(143,265
|
)
|
(59,154
|
)
|
(347,607
|
)
|
(202,172
|
)
|
||||||||
|
Other income (expense):
|
||||||||||||||||
|
Investment income
|
23,935
|
7,524
|
63,355
|
13,447
|
||||||||||||
|
Interest expense
|
(4,203
|
)
|
(2,139
|
)
|
(8,102
|
)
|
(6,391
|
)
|
||||||||
|
Interest expense related to sale of future royalties
|
(17,779
|
)
|
—
|
(50,948
|
)
|
—
|
||||||||||
|
Gain (loss) on investments
|
(1,943
|
)
|
2,347
|
(1,753
|
)
|
(10,616
|
)
|
|||||||||
|
Other income (expense)
|
2,447
|
4,713
|
13,857
|
(7,923
|
)
|
|||||||||||
|
Loss before income tax expense
|
(140,808
|
)
|
(46,709
|
)
|
(331,198
|
)
|
(213,655
|
)
|
||||||||
|
Income tax expense
|
(6,602
|
)
|
(283
|
)
|
(25,825
|
)
|
(3,637
|
)
|
||||||||
|
Net loss
|
$
|
(147,410
|
)
|
$
|
(46,992
|
)
|
$
|
(357,023
|
)
|
$
|
(217,292
|
)
|
||||
|
Basic and diluted net loss per share
|
$
|
(1.03
|
)
|
$
|
(0.33
|
)
|
$
|
(2.50
|
)
|
$
|
(1.53
|
)
|
||||
|
Shares used in computing basic and diluted net loss per share
|
143,317
|
141,950
|
143,052
|
141,782
|
||||||||||||
See accompanying notes.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands)
(Unaudited)
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Net loss
|
$
|
(147,410
|
)
|
$
|
(46,992
|
)
|
$
|
(357,023
|
)
|
$
|
(217,292
|
)
|
||||
|
Unrealized gains (losses) on debt securities, net of tax
|
5,029
|
(8,734
|
)
|
11,421
|
(29,508
|
)
|
||||||||||
|
Currency translation adjustment
|
(153
|
)
|
(399
|
)
|
22
|
(964
|
)
|
|||||||||
|
Comprehensive loss
|
$
|
(142,534
|
)
|
$
|
(56,125
|
)
|
$
|
(345,580
|
)
|
$
|
(247,764
|
)
|
||||
See accompanying notes.
CONDENSED CONSOLIDATED STATEMENTS OF
STOCKHOLDERS’ EQUITY
(in thousands)
(Unaudited)
|
Common Stock
|
Additional
|
Accumulated Other
|
Accumulated
|
Total
Stockholders’
|
||||||||||||||||||||
|
Description
|
Shares
|
Amount
|
Paid in Capital
|
Comprehensive Loss
|
Deficit
|
Equity
|
||||||||||||||||||
|
Balance at June 30, 2022
|
141,831
|
$
|
142
|
$
|
2,008,794
|
$
|
(54,007
|
)
|
$
|
(1,330,203
|
)
|
$
|
624,726
|
|||||||||||
|
Net loss
|
—
|
—
|
—
|
—
|
(46,992
|
)
|
(46,992
|
)
|
||||||||||||||||
|
Change in unrealized losses, net of tax
|
—
|
—
|
—
|
(8,734
|
)
|
—
|
(8,734
|
)
|
||||||||||||||||
|
Foreign currency translation
|
—
|
—
|
—
|
(399
|
)
|
—
|
(399
|
)
|
||||||||||||||||
|
Issuance of common stock in connection with employee stock plans
|
203
|
—
|
2,567
|
—
|
—
|
2,567
|
||||||||||||||||||
|
Stock-based compensation expense
|
—
|
—
|
23,837
|
—
|
—
|
23,837
|
||||||||||||||||||
|
Payments of tax withholdings related to vesting of employee stock awards and exercise of employee
stock options
|
(17
|
)
|
—
|
(644
|
)
|
—
|
—
|
(644
|
)
|
|||||||||||||||
|
Balance at September 30, 2022
|
142,017
|
$
|
142
|
$
|
2,034,554
|
$
|
(63,140
|
)
|
$
|
(1,377,195
|
)
|
$
|
594,361
|
|||||||||||
|
Balance at June 30, 2023
|
143,167
|
$
|
143
|
$
|
2,118,309
|
$
|
(50,913
|
)
|
$
|
(1,639,238
|
)
|
$
|
428,301
|
|||||||||||
|
Net loss
|
—
|
—
|
—
|
—
|
(147,410
|
)
|
(147,410
|
)
|
||||||||||||||||
|
Change in unrealized losses, net of tax
|
—
|
—
|
—
|
5,029
|
—
|
5,029
|
||||||||||||||||||
|
Foreign currency translation
|
—
|
—
|
—
|
(153
|
)
|
—
|
(153
|
)
|
||||||||||||||||
|
Issuance of common stock in connection with employee stock plans
|
226
|
—
|
3,729
|
—
|
—
|
3,729
|
||||||||||||||||||
|
Stock-based compensation expense
|
—
|
—
|
25,964
|
—
|
—
|
25,964
|
||||||||||||||||||
|
Balance at September 30, 2023
|
143,393
|
$
|
143
|
$
|
2,148,002
|
$
|
(46,037
|
)
|
$
|
(1,786,648
|
)
|
$
|
315,460
|
|||||||||||
See accompanying notes.
IONIS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF
STOCKHOLDERS’ EQUITY
(in thousands)
(Unaudited)
|
Common Stock
|
Additional
|
Accumulated Other
|
Accumulated
|
Total
Stockholders’
|
||||||||||||||||||||
|
Description
|
Shares
|
Amount
|
Paid in Capital
|
Comprehensive Loss
|
Deficit
|
Equity
|
||||||||||||||||||
|
Balance at December 31, 2021
|
141,210
|
$
|
141
|
$
|
1,964,167
|
$
|
(32,668
|
)
|
$
|
(1,159,903
|
)
|
$
|
771,737
|
|||||||||||
|
Net loss
|
—
|
—
|
—
|
—
|
(217,292
|
)
|
(217,292
|
)
|
||||||||||||||||
|
Change in unrealized losses, net of tax
|
—
|
—
|
—
|
(29,508
|
)
|
—
|
(29,508
|
)
|
||||||||||||||||
|
Foreign currency translation
|
—
|
—
|
—
|
(964
|
)
|
—
|
(964
|
)
|
||||||||||||||||
|
Issuance of common stock in connection with employee stock plans
|
1,138
|
1
|
6,029
|
—
|
—
|
6,030
|
||||||||||||||||||
|
Stock-based compensation expense
|
—
|
—
|
74,575
|
—
|
—
|
74,575
|
||||||||||||||||||
|
Payments of tax withholdings related to vesting of employee stock awards and exercise of employee
stock options
|
(331
|
)
|
—
|
(10,217
|
)
|
—
|
—
|
(10,217
|
)
|
|||||||||||||||
|
Balance at September 30, 2022
|
142,017
|
$
|
142
|
$
|
2,034,554
|
$
|
(63,140
|
)
|
$
|
(1,377,195
|
)
|
$
|
594,361
|
|||||||||||
|
Balance at December 31, 2022
|
142,058
|
$
|
142
|
$
|
2,059,850
|
$
|
(57,480
|
)
|
$
|
(1,429,625
|
)
|
$
|
572,887
|
|||||||||||
|
Net loss
|
—
|
—
|
—
|
—
|
(357,023
|
)
|
(357,023
|
)
|
||||||||||||||||
|
Change in unrealized gains, net of tax
|
—
|
—
|
—
|
11,421
|
—
|
11,421
|
||||||||||||||||||
|
Foreign currency translation
|
—
|
—
|
—
|
22
|
—
|
22
|
||||||||||||||||||
|
Issuance of common stock in connection with employee stock plans
|
1,335
|
1
|
8,679
|
—
|
—
|
8,680
|
||||||||||||||||||
|
Stock-based compensation expense
|
—
|
—
|
79,473
|
—
|
—
|
79,473
|
||||||||||||||||||
|
Balance at September 30, 2023
|
143,393
|
$
|
143
|
$
|
2,148,002
|
$
|
(46,037
|
)
|
$
|
(1,786,648
|
)
|
$
|
315,460
|
|||||||||||
See accompanying notes.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
|
Nine Months Ended
September 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Operating activities:
|
||||||||
|
Net loss
|
$
|
(357,023
|
)
|
$
|
(217,292
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation
|
7,748
|
11,301
|
||||||
|
Amortization of right-of-use operating lease assets
|
7,234
|
1,970
|
||||||
|
Amortization of other assets
|
1,904
|
1,805
|
||||||
|
Amortization of premium (discount) on investments, net
|
(20,396
|
)
|
9,072
|
|||||
|
Amortization of debt issuance costs
|
4,666
|
4,035
|
||||||
|
Non-cash royalty revenue related to sale of royalties
|
(27,814
|
)
|
—
|
|||||
|
Non-cash interest related to sale of future royalties
|
50,541
|
—
|
||||||
|
Stock-based compensation expense
|
79,473
|
74,575
|
||||||
|
Loss on investments
|
1,429
|
228
|
||||||
|
Gain on early retirement of debt
|
(13,389
|
)
|
—
|
|||||
|
Non-cash losses related to disposal of property, plant and equipment
|
14,646
|
528
|
||||||
|
Non-cash losses related to other assets
|
849
|
1,155
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Contracts receivable
|
(116,814
|
)
|
55,251
|
|||||
|
Inventories
|
(3,601
|
)
|
4,161
|
|||||
|
Other current and long-term assets
|
(18,325
|
)
|
(988
|
)
|
||||
|
Income taxes payable
|
24,821
|
(20
|
)
|
|||||
|
Accounts payable
|
(12,462
|
)
|
5,607
|
|||||
|
Accrued compensation
|
(15,397
|
)
|
(8,400
|
)
|
||||
|
Accrued liabilities and other current liabilities
|
(24,219
|
)
|
38,263
|
|||||
|
Deferred contract revenue
|
75,751
|
(55,426
|
)
|
|||||
|
Net cash used in operating activities
|
(340,378
|
)
|
(74,175
|
)
|
||||
|
Investing activities:
|
||||||||
|
Purchases of short-term investments
|
(1,353,100
|
)
|
(1,223,791
|
)
|
||||
|
Proceeds from sale of short-term investments
|
1,193,724
|
764,101
|
||||||
|
Purchases of property, plant and equipment
|
(24,624
|
)
|
(11,582
|
)
|
||||
|
Acquisition of licenses and other assets, net
|
(3,414
|
)
|
(3,511
|
)
|
||||
|
Net cash used in investing activities
|
(187,414
|
)
|
(474,783
|
)
|
||||
|
Financing activities:
|
||||||||
|
Proceeds from equity, net
|
8,680
|
6,030
|
||||||
|
Payments of tax withholdings related to vesting of employee stock awards and exercise of
employee stock options
|
—
|
(10,217
|
)
|
|||||
|
Proceeds from issuance of 1.75 percent convertible senior notes
|
575,000
|
—
|
||||||
|
1.75 percent convertible senior notes issuance costs
|
(14,175
|
)
|
—
|
|||||
|
Repurchase of $504.4 million principal amount of 0.125 percent convertible senior notes
|
(487,943
|
)
|
—
|
|||||
|
Proceeds from sale of future royalties
|
500,000
|
—
|
||||||
|
Payments of transaction costs related to sale of future royalties
|
(10,434
|
)
|
—
|
|||||
|
Proceeds from real estate transaction
|
32,352
|
—
|
||||||
|
Principal payments on mortgage debt
|
(122
|
)
|
(89
|
)
|
||||
|
Net cash provided by (used in) financing activities
|
603,358
|
(4,276
|
)
|
|||||
|
Effects of exchange rates on cash
|
22
|
(964
|
)
|
|||||
|
Net increase (decrease) in cash and cash equivalents
|
75,588
|
(554,198
|
)
|
|||||
|
Cash and cash equivalents at beginning of period
|
276,472
|
869,191
|
||||||
|
Cash and cash equivalents at end of period
|
$
|
352,060
|
$
|
314,993
|
||||
|
Supplemental disclosures of cash flow information:
|
||||||||
|
Interest paid
|
$
|
952
|
$
|
2,204
|
||||
|
Income taxes paid
|
$
|
714
|
$
|
2
|
||||
|
Supplemental disclosures of non-cash investing and financing activities:
|
||||||||
|
Amounts accrued for capital and patent expenditures
|
$
|
341
|
$
|
3,032
|
||||
|
Right-of-use assets obtained in exchange for lease liabilities
|
$
|
—
|
$
|
657
|
||||
See accompanying notes.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)
1. Organization and Basis of Presentation
Organization and Business Activity
We incorporated in California on January 10, 1989. In conjunction with our initial public offering, we reorganized as a Delaware
corporation in April 1991. We are a leader in the discovery and development of RNA-targeted therapeutics.
Basis of Presentation
We prepared the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2023 and 2022 on the same basis as the audited financial statements for the year ended December 31, 2022. We included all normal recurring adjustments in the financial statements, which we considered necessary for a fair presentation of our financial position at such dates and our
operating results and cash flows for those periods. Our operating results for the interim periods may not be indicative of what our operating results will be for the entire year. For more complete financial information, these financial statements, and
notes thereto, should be read in conjunction with the audited financial statements for the year ended December 31, 2022 included in our Annual
Report on Form 10-K filed with the Securities and Exchange Commission, or SEC.
In our condensed consolidated financial statements, we included the accounts of Ionis Pharmaceuticals, Inc. and the
consolidated results of our wholly owned subsidiary, Akcea Therapeutics, Inc. and its wholly owned subsidiaries (“we”, “us” or “our”).
We operate as a
segment, Ionis operations, because our chief decision maker reviews operating results on an aggregate basis and manages our operations as a
operating segment.
Use of Estimates
We prepare our condensed consolidated
financial statements in conformity with accounting principles generally accepted in the United States, or U.S., that require us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial
statements and accompanying notes. Actual results could differ from our estimates.
2. Significant Accounting Policies
Our significant accounting policies have not changed substantially from those included in our Annual Report on Form 10-K
for the year ended December 31, 2022, other than as discussed below.
Liability Related to Sale of Future Royalties
In January 2023, we entered into a royalty purchase agreement with Royalty Pharma Investments, or Royalty Pharma, to
monetize a portion of our future SPINRAZA and pelacarsen royalties we are entitled to under our arrangements with Biogen and Novartis, respectively. Refer to Note 11, Liability Related to Sale of Future Royalties, for further details on the agreement.
Under our agreement with Royalty Pharma, we record upfront payments and milestone payments we receive from the sale of
future royalties as a liability, net of transaction costs. We record royalty payments made to Royalty Pharma as a reduction of the liability and amortize the transaction costs over the estimated life of the royalty stream. We account for the associated
interest expense under the effective interest rate method, while continuing to recognize the full amount of royalty revenue in the period in which the counterparty sells the related product and recognizes the related revenue.
We calculate the liability related to the sale of future royalties, effective interest rate and the related interest
expense using our current estimate of anticipated future royalty payments under the arrangement, which we periodically reassess based on internal projections and information from our partners who are responsible for commercializing the medicines. If
there is a material change in our estimate, we will prospectively adjust the liability related to the sale of future royalties, effective interest rate and the related interest expense.
Recently Adopted Accounting Standards
We do not expect any recently issued accounting standards to have a material impact to our financial results.
3. Supplemental Financial Data
Inventories
Our inventory consisted of the following (in thousands):
|
September 30, 2023
|
December 31, 2022
|
|||||||
|
Raw materials:
|
||||||||
|
Raw materials - clinical
|
$
|
18,427
|
$
|
17,061
|
||||
|
Raw materials - commercial
|
4,380
|
2,699
|
||||||
|
Total raw materials
|
22,807
|
19,760
|
||||||
|
Work in process
|
2,651
|
2,109
|
||||||
|
Finished goods
|
176
|
164
|
||||||
|
Total inventory
|
$
|
25,634
|
$
|
22,033
|
||||
Accrued Liabilities
Our accrued liabilities consisted of the following (in thousands):
|
September 30, 2023
|
December 31, 2022
|
|||||||
|
Clinical development expenses
|
$
|
89,217
|
$
|
116,460
|
||||
|
In-licensing expenses
|
7,560
|
7,945
|
||||||
|
Commercial expenses
|
8,575
|
3,498
|
||||||
|
Other miscellaneous expenses
|
13,616
|
12,198
|
||||||
|
Total accrued liabilities
|
$
|
118,968
|
$
|
140,101
|
||||
4. Revenues
During the three and nine months ended September 30, 2023 and 2022, our revenues
were comprised of the following (in thousands):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Revenue:
|
||||||||||||||||
|
Commercial revenue:
|
||||||||||||||||
|
SPINRAZA royalties
|
$
|
67,253
|
$
|
61,647
|
$
|
178,511
|
$
|
175,092
|
||||||||
|
Other commercial revenue:
|
||||||||||||||||
|
TEGSEDI and WAYLIVRA revenue, net
|
8,286
|
5,920
|
25,420
|
22,467
|
||||||||||||
|
Licensing and other royalty revenue
|
8,542
|
4,843
|
25,815
|
25,320
|
||||||||||||
|
Total other commercial revenue
|
16,828
|
10,763
|
51,235
|
47,787
|
||||||||||||
|
Total commercial revenue
|
84,081
|
72,410
|
229,746
|
222,879
|
||||||||||||
|
Research and development revenue:
|
||||||||||||||||
|
Collaborative agreement revenue
|
44,167
|
69,250
|
173,513
|
157,282
|
||||||||||||
|
Eplontersen joint development revenue
|
15,959
|
18,107
|
59,883
|
55,317
|
||||||||||||
|
Total research and development revenue
|
60,126
|
87,357
|
233,396
|
212,599
|
||||||||||||
|
Total revenue
|
$
|
144,207
|
$
|
159,767
|
$
|
463,142
|
$
|
435,478
|
||||||||
Refer to Note 5, Collaborative
Arrangements and Licensing Agreements, for further details on our collaborative agreement revenue.
5. Collaborative Arrangements and Licensing Agreements
Below, we have included our AstraZeneca,
Biogen, GSK, Novartis, Roche and Sobi collaborations, which are the collaborations with substantive changes during 2023 from those included
in Part IV, Item 15, Note 7, Collaborative Arrangements and Licensing Agreements, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.
AstraZeneca
We have two collaborations with AstraZeneca, one focused on the joint development and commercialization of
eplontersen for the treatment of transthyretin amyloidosis, or ATTR, and one focused on the treatment of cardiovascular, renal and metabolic diseases. From inception through September 30, 2023, we have received nearly $650 million from these collaborations.
We are jointly developing and preparing to
commercialize eplontersen with AstraZeneca in the U.S. In addition, we granted AstraZeneca exclusive rights to commercialize eplontersen outside the U.S. In the second quarter of 2023, we earned a $20 million license fee payment when we licensed rights to Latin America for eplontersen
to AstraZeneca. We recognized the upfront payment in full in the second quarter of 2023 because AstraZeneca had full use of the license without any continuing involvement from us. We will achieve the next payment of $50 million upon regulatory approval in the U.S. under this collaboration.
Under our collaboration for cardiovascular,
renal and metabolic diseases, AstraZeneca has licensed multiple medicines from us. AstraZeneca is responsible for global development, regulatory and commercialization activities and costs for each of the medicines it has licensed from us. In the
second quarter of 2023, we earned a $20 million milestone payment when AstraZeneca initiated a Phase 2b study for ION839, an
investigational ligand-conjugated antisense, or LICA, medicine designed to inhibit the production of patatin-like phospholipase domain-containing 3, or PNPLA3, protein. We recognized this milestone payment as R&D revenue in full in the second
quarter of 2023 because we did not have any remaining performance obligations related to the milestone payment. We will achieve the next payment of up to $30
million if AstraZeneca licenses a medicine under this collaboration.
During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentages):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Revenue from our relationship with AstraZeneca
|
$
|
15,959
|
$
|
18,107
|
$
|
99,885
|
$
|
55,718
|
||||||||
|
Percentage of total revenue
|
11
|
%
|
11
|
%
|
22
|
%
|
13
|
%
|
||||||||
We did not
have any deferred contract revenue from our relationship with AstraZeneca at September 30, 2023 or December 31, 2022.
Biogen
We have several strategic collaborations with
Biogen focused on using antisense technology to advance the treatment of neurological disorders. We developed and licensed to Biogen SPINRAZA, our approved medicine to treat people with spinal muscular atrophy, or SMA. Under our 2013 strategic
neurology collaboration, Biogen developed QALSODY (tofersen), our recently approved medicine in the U.S. to treat patients with superoxide dismutase 1 amyotrophic lateral sclerosis, or SOD1-ALS. Under our collaborations, we and Biogen are currently
developing numerous investigational medicines to treat neurodegenerative diseases in addition to SMA and SOD1-ALS, including medicines in development to treat people with amyotrophic lateral sclerosis, or ALS, Angelman Syndrome, or AS, Alzheimer’s disease, or AD, and Parkinson’s disease, or PD. In addition to these medicines, our collaborations with Biogen include a substantial research pipeline that addresses a broad range of neurological diseases. From inception through September 30, 2023, we have received more than $3.6 billion in payments from our Biogen collaborations.
Under our 2013 strategic neurology collaboration, we earned a $16 million milestone payment from Biogen when the U.S. Food and Drug Administration, or FDA, approved Biogen’s New Drug Application, or NDA, for QALSODY in the second quarter of 2023. We
recognized this milestone payment as R&D revenue in full in the second quarter of 2023 because we did not have any remaining performance obligations related to the milestone payment. Under our collaboration agreement with Biogen, we are eligible to
receive tiered royalties ranging from 11 percent to 15 percent on sales of QALSODY. Following the NDA approval in April 2023, we began earning royalties from QALSODY sales, which we recognize as other commercial revenue in our condensed
consolidated statements of operations. We will achieve the next milestone payment for QALSODY of $20 million if the European Medicines Agency
approves Biogen’s Marketing Authorization Application, filing of QALSODY.
Under our 2012 neurology collaboration, we achieved $21 million in milestone payments from Biogen when Biogen advanced ION582, our investigational antisense medicine for the potential treatment of AS, in the third quarter of 2023. We are
recognizing these milestone payments as revenue as we perform services based on our effort to satisfy our R&D services performance obligation relative to the total effort expected to satisfy our performance obligation for ION582.
During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with Biogen (in thousands, except percentages):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Revenue from our relationship with Biogen
|
$
|
94,695
|
$
|
88,959
|
$
|
262,599
|
$
|
259,713
|
||||||||
|
Percentage of total revenue
|
66
|
%
|
56
|
%
|
57
|
%
|
60
|
%
|
||||||||
In October 2023, we earned a milestone payment of $9 million from Biogen when we advanced ION582 under our 2012 neurology collaboration. We will achieve the next payment of $70 million if Biogen licenses ION582 under this collaboration.
Our condensed consolidated balance sheets at September 30, 2023 and December 31, 2022 included deferred contract revenue of $316.8 million and $351.2 million, respectively, from our relationship with Biogen.
GSK
In March 2010, we entered into a
collaboration with GSK using our antisense drug discovery platform to discover and develop new medicines against targets for serious and rare diseases, including infectious diseases and some conditions causing blindness. Our collaboration with GSK
currently includes bepirovirsen, our medicine in development for the treatment of hepatitis B virus, or HBV, infection. In the third quarter of 2019, following positive Phase 2 results, GSK licensed our HBV program. GSK is responsible for all global
development, regulatory and commercialization activities and costs for the HBV program. From inception through September 30, 2023, we
have received more than $105 million in an upfront payment and payments related to the HBV program.
In the first quarter of 2023, we earned a $15 million milestone payment when GSK initiated a Phase 3 program of bepirovirsen. We recognized this milestone payment as R&D revenue in full in the first quarter of 2023 because we did not
have any remaining performance obligations related to the milestone payment. We will achieve the next payment of $15 million if the FDA accepts
an NDA filing of bepirovirsen for review.
During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with GSK (in thousands, except percentages):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Revenue from our relationship with GSK
|
$
|
—
|
$
|
—
|
$
|
15,000
|
$
|
—
|
||||||||
|
Percentage of total revenue
|
0
|
%
|
0
|
%
|
3
|
%
|
0
|
%
|
||||||||
We did not
have any deferred contract revenue from our relationship with GSK at September 30, 2023 or December 31, 2022.
Novartis
In January 2017, we initiated a collaboration with Novartis to develop and commercialize pelacarsen, an
investigational medicine for patients with elevated lipoprotein(a), or Lp(a)-driven cardiovascular disease, or CVD. Novartis is responsible for conducting and funding development and regulatory activities for pelacarsen, including a global Phase 3
cardiovascular outcomes study, which Novartis initiated in December 2019.
In August 2023, we entered into a
collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with Lp(a)-driven CVD. Novartis is solely responsible for the development, manufacturing and potential
commercialization of the next generation Lp(a) therapy. In September 2023, this agreement received clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Novartis paid us a $60 million upfront payment in October 2023 and we are eligible to receive development, regulatory
and commercial milestone payments and tiered royalties ranging from 10 percent to 20 percent on net sales
of any product resulting from this collaboration.
At the commencement of this collaboration, we identified one performance obligation, which was to perform R&D services for Novartis. We included the upfront payment in our transaction price for our R&D services performance obligation. We are
recognizing revenue for our R&D services performance obligation as we perform services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. We will achieve the next
payment of $5 million if we designate a development candidate under this collaboration.
From inception through September 30, 2023, we have received more than $275 million in payments from our Novartis collaborations.
During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with Novartis (in thousands, except percentages):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Revenue from our relationship with Novartis
|
$
|
1,908
|
$
|
—
|
$
|
2,023
|
$
|
—
|
||||||||
|
Percentage of total revenue
|
1
|
%
|
0
|
%
|
0
|
%
|
0
|
%
|
||||||||
Our condensed consolidated balance sheet at September 30, 2023 included deferred contract revenue of $58.1 million from our
relationship with Novartis. We did not have any deferred contract revenue from our relationship with Novartis at December 31, 2022.
Roche
We have three
collaborations with Hoffmann-La Roche Inc and F. Hoffmann-La Roche Ltd, collectively Roche: one to develop treatments for Huntington’s disease, or HD, one to develop IONIS-FB-LRx for the treatment of complement-mediated diseases, and one to develop RNA-targeted programs for AD and HD.
In September 2023, we entered into an agreement with Roche to develop two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of AD and HD. Under the agreement, we are responsible for advancing the two programs through preclinical studies and Roche is responsible for clinical development, manufacturing and commercialization of the medicines if they
receive regulatory approval. Roche paid us a $60 million upfront payment in October 2023 and we are eligible to receive development, regulatory
and commercial milestone payments and tiered royalties up to the mid-teens on net sales of any product resulting from this collaboration.
We identified two performance
obligations under this new agreement, comprised of R&D services for each of the two separate programs. We included the upfront payment in our transaction price for our R&D services performance obligations. We are recognizing revenue for our R&D services performance obligations
as we perform services based on our effort to satisfy our performance obligations relative to our total effort expected to satisfy our performance obligations. We will achieve the next payment of $7.5 million if we advance a medicine under this collaboration.
From inception through September 30, 2023, we have received more than $285 million in payments from our Roche collaborations.
During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with Roche (in thousands, except percentage amounts):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
R&D revenue
|
$
|
8,858
|
$
|
41,504
|
$
|
16,979
|
$
|
65,360
|
||||||||
|
Percentage of total revenue
|
6
|
%
|
26
|
%
|
4
|
%
|
15
|
%
|
||||||||
Our condensed consolidated balance sheets at September 30, 2023 and December 31, 2022 included deferred contract revenue of $68.0 million and $22.4 million, respectively,
from our relationship with Roche.
Swedish Orphan Biovitrum AB (Sobi)
We began commercializing TEGSEDI and WAYLIVRA in Europe in January 2021 and TEGSEDI in North America in April 2021 through
distribution agreements with Swedish Orphan Biovitrum AB, or Sobi. Under our agreements, we are responsible for supplying finished goods inventory to Sobi and Sobi is responsible for selling each medicine to the end customer. In exchange, we earn a
distribution fee on net sales from Sobi for each medicine.
In October 2023, our distribution agreement for TEGSEDI in North America was terminated. During
the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our distribution agreement with Sobi for TEGSEDI in North America (in thousands, except percentage amounts).
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
TEGSEDI revenue from our distribution agreement with Sobi in North America
|
$
|
794
|
$
|
1,008
|
$
|
2,189
|
$
|
3,443
|
||||||||
|
Percentage of total revenue
|
1
|
%
|
1
|
%
|
2
|
%
|
1
|
%
|
||||||||
6. Basic and Diluted Net Loss Per Share
Basic net loss per share
We calculated our basic net loss per share for the three and nine months ended September 30, 2023 and 2022 by dividing our net loss by our weighted-average number of common shares outstanding during the period.
Diluted net loss per share
For the three and nine months ended September 30, 2023 and 2022, we incurred a net loss; therefore, we did not include dilutive common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.
Common stock from the following would have had an anti-dilutive effect on net loss per share:
| ● |
1.75 percent convertible senior notes, or 1.75% Notes;
|
| ● |
0 percent convertible senior notes, or 0% Notes;
|
| ● |
Note hedges related to the 0% Notes;
|
| ● |
0.125 percent convertible senior notes, or
0.125% Notes;
|
| ● |
Note hedges related to the 0.125% Notes;
|
| ● |
Dilutive stock options;
|
| ● |
Unvested restricted stock units, or RSUs;
|
| ● |
Unvested performance restricted stock units, or PRSUs; and
|
| ● |
Employee Stock Purchase Plan, or ESPP.
|
Additionally as of September 30, 2023,
we had warrants related to our 0% and 0.125%
Notes outstanding. We will include the shares issuable under these warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants.
7. Investments
The following table summarizes the contract maturity of the available-for-sale securities we held as of September 30, 2023:
|
One year or less
|
72
|
%
|
||
|
After one year but within two years
|
20
|
%
|
||
|
After two years but within
|
8
|
%
|
||
|
Total
|
100
|
%
|
As illustrated above, at September 30, 2023, 92 percent of our available-for-sale securities had a maturity of less than two years.
All of our available-for-sale debt securities are available to us for use in our current operations. As a result, we
categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.
We invest in debt securities with
strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Standard & Poor’s, Moody’s or Fitch, respectively.
At September 30, 2023,
we had an equity ownership interest of less than 20 percent in seven private companies and three public companies with which we conduct business.
The following is a summary of our investments (in thousands):
|
Amortized
|
Gross Unrealized
|
Estimated
|
||||||||||||||
|
September 30, 2023
|
Cost
|
Gains
|
Losses
|
Fair Value
|
||||||||||||
|
Available-for-sale debt securities:
|
||||||||||||||||
|
Corporate debt securities (1)
|
$
|
535,408
|
$
|
13
|
$
|
(4,492
|
)
|
$
|
530,929
|
|||||||
|
Debt securities issued by U.S. government agencies
|
267,503
|
—
|
(1,429
|
)
|
266,074
|
|||||||||||
|
Debt securities issued by the U.S. Treasury (1)
|
520,013
|
1
|
(3,027
|
)
|
516,987
|
|||||||||||
|
Debt securities issued by states of the U.S. and political subdivisions of the states
|
23,906
|
—
|
(242
|
)
|
23,664
|
|||||||||||
|
Total debt securities with a maturity of one year or less
|
1,346,830
|
14
|
(9,190
|
)
|
1,337,654
|
|||||||||||
|
Corporate debt securities
|
195,674
|
183
|
(3,160
|
)
|
192,697
|
|||||||||||
|
Debt securities issued by U.S. government agencies
|
56,365
|
—
|
(507
|
)
|
55,858
|
|||||||||||
|
Debt securities issued by the U.S. Treasury
|
297,501
|
—
|
(3,364
|
)
|
294,137
|
|||||||||||
|
Debt securities issued by states of the U.S. and political subdivisions of the states
|
4,164
|
53
|
(51
|
)
|
4,166
|
|||||||||||
|
Total debt securities with a maturity of more than one year
|
553,704
|
236
|
(7,082
|
)
|
546,858
|
|||||||||||
|
Total available-for-sale debt securities
|
$
|
1,900,534
|
$
|
250
|
$
|
(16,272
|
)
|
$
|
1,884,512
|
|||||||
|
Equity securities:
|
||||||||||||||||
|
Publicly traded equity securities included in other current assets (2)
|
$
|
11,897
|
$
|
(1,252
|
)
|
$
|
(4,083
|
)
|
$
|
6,562
|
||||||
|
Privately held equity securities included in deposits and other assets (3)
|
23,115
|
25,001
|
(5,125
|
)
|
42,991
|
|||||||||||
|
Total equity securities
|
35,012
|
23,749
|
(9,208
|
)
|
49,553
|
|||||||||||
|
Total available-for-sale debt and equity securities
|
$
|
1,935,546
|
$
|
23,999
|
$
|
(25,480
|
)
|
$
|
1,934,065
|
|||||||
|
Amortized
|
Gross Unrealized
|
Estimated
|
||||||||||||||
|
December 31, 2022
|
Cost
|
Gains
|
Losses
|
Fair Value
|
||||||||||||
|
Available-for-sale debt securities:
|
||||||||||||||||
|
Corporate debt securities (1)
|
$
|
513,790
|
$
|
23
|
$
|
(4,365
|
)
|
$
|
509,448
|
|||||||
|
Debt securities issued by U.S. government agencies
|
133,585
|
—
|
(1,829
|
)
|
131,756
|
|||||||||||
|
Debt securities issued by the U.S. Treasury (1)
|
512,655
|
23
|
(5,124
|
)
|
507,554
|
|||||||||||
|
Debt securities issued by states of the U.S. and political subdivisions of the states
|
57,484
|
18
|
(686
|
)
|
56,816
|
|||||||||||
|
Other municipal debt securities
|
6,008
|
—
|
(14
|
)
|
5,994
|
|||||||||||
|
Total debt securities with a maturity of one year or less
|
1,223,522
|
64
|
(12,018
|
)
|
1,211,568
|
|||||||||||
|
Corporate debt securities
|
227,631
|
14
|
(10,143
|
)
|
217,502
|
|||||||||||
|
Debt securities issued by U.S. government agencies
|
34,339
|
—
|
(1,040
|
)
|
33,299
|
|||||||||||
|
Debt securities issued by the U.S. Treasury
|
245,030
|
—
|
(4,109
|
)
|
240,921
|
|||||||||||
|
Debt securities issued by states of the U.S. and political subdivisions of the states
|
18,314
|
116
|
(329
|
)
|
18,101
|
|||||||||||
|
Total debt securities with a maturity of more than one year
|
525,314
|
130
|
(15,621
|
)
|
509,823
|
|||||||||||
|
Total available-for-sale debt securities
|
$
|
1,748,836
|
$
|
194
|
$
|
(27,639
|
)
|
$
|
1,721,391
|
|||||||
|
Equity securities:
|
||||||||||||||||
|
Publicly traded equity securities included in other current assets (2)
|
$
|
11,897
|
$
|
—
|
$
|
(1,358
|
)
|
$
|
10,539
|
|||||||
|
Privately held equity securities included in deposits and other assets (3)
|
23,115
|
17,257
|
—
|
40,372
|
||||||||||||
|
Total equity securities
|
35,012
|
17,257
|
(1,358
|
)
|
50,911
|
|||||||||||
|
Total available-for-sale debt and equity securities
|
$
|
1,783,848
|
$
|
17,451
|
$
|
(28,997
|
)
|
$
|
1,772,302
|
|||||||
| (1) |
Includes investments classified
as cash equivalents in our condensed consolidated balance sheets.
|
| (2) |
Our publicly traded equity
securities are included in other current assets. We recognize publicly traded equity securities at fair value. In the nine months ended September 30, 2023, we recognized a $4.0
million unrealized loss in our condensed consolidated statements of operations related to a decrease in the fair value of our investments in publicly traded companies.
|
| (3) |
Our privately held equity securities are included in deposits and other assets. We recognize our privately held equity securities at cost minus impairments, plus or minus changes
resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer, which are Level 3 inputs.
In the nine months ended September 30, 2023, we recorded a net gain of $2.6 million in our condensed consolidated statements of
operations related to changes in the fair value of our investments in privately held companies.
|
The following is a summary of our investments we consider to be temporarily impaired at September 30, 2023 (in thousands, except for number of investments):
|
Less than 12 Months of
Temporary Impairment
|
More than 12 Months of
Temporary Impairment
|
Total Temporary
Impairment
|
||||||||||||||||||||||||||
|
Number of
Investments
|
Estimated
Fair Value
|
Unrealized
Losses
|
Estimated
Fair Value
|
Unrealized
Losses
|
Estimated
Fair Value
|
Unrealized
Losses
|
||||||||||||||||||||||
|
Corporate debt securities
|
370
|
$
|
469,095
|
$
|
(2,390
|
)
|
$
|
207,073
|
$
|
(5,262
|
)
|
$
|
676,168
|
$
|
(7,652
|
)
|
||||||||||||
|
Debt securities issued by U.S. government agencies
|
98
|
293,408
|
(1,242
|
)
|
24,531
|
(694
|
)
|
317,939
|
(1,936
|
)
|
||||||||||||||||||
|
Debt securities issued by the U.S. Treasury
|
68
|
557,489
|
(3,420
|
)
|
225,634
|
(2,971
|
)
|
783,123
|
(6,391
|
)
|
||||||||||||||||||
|
Debt securities issued by states of the U.S. and political subdivisions of the states
|
85
|
11,644
|
(73
|
)
|
12,973
|
(220
|
)
|
24,617
|
(293
|
)
|
||||||||||||||||||
|
Total temporarily impaired securities
|
621
|
$
|
1,331,636
|
$
|
(7,125
|
)
|
$
|
470,211
|
$
|
(9,147
|
)
|
$
|
1,801,847
|
$
|
(16,272
|
)
|
||||||||||||
We believe that the decline in value of these securities is temporary and is primarily related to the change in market interest rates
since purchase rather than underlying credit deterioration for any of the issuers. We believe it is more likely than not that we will be able to hold our debt securities with declines in value to maturity. Therefore, we intend to hold these securities
to maturity and anticipate full recovery of our debt securities’ amortized cost basis at maturity.
8. Fair Value Measurements
The following tables present the major security types we held at September 30, 2023 and December 31, 2022
that we regularly measure and carry at fair value. The following tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective security’s fair value (in thousands):
|
At
September 30, 2023
|
Quoted Prices in
Active Markets
(Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
||||||||||
|
Cash equivalents (1)
|
$
|
269,255
|
$
|
269,255
|
$
|
—
|
||||||
|
Corporate debt securities (2)
|
723,626
|
—
|
723,626
|
|||||||||
|
Debt securities issued by U.S. government agencies (3)
|
321,932
|
—
|
321,932
|
|||||||||
|
Debt securities issued by the U.S. Treasury (2)
|
811,124
|
811,124
|
—
|
|||||||||
|
Debt securities issued by states of the U.S. and political subdivisions of the states (2)
|
27,830
|
—
|
27,830
|
|||||||||
|
Publicly traded equity securities included in other current assets (4)
|
6,562
|
6,562
|
—
|
|||||||||
|
Total
|
$
|
2,160,329
|
$
|
1,086,941
|
$
|
1,073,388
|
||||||
|
At
December 31, 2022
|
Quoted Prices in
Active Markets
(Level 1)
|
Significant Other
Observable Inputs
(Level 2)
|
||||||||||
|
Cash equivalents (1)
|
$
|
211,655
|
$
|
211,655
|
$
|
—
|
||||||
|
Corporate debt securities (5)
|
726,950
|
—
|
726,950
|
|||||||||
|
Debt securities issued by U.S. government agencies (2)
|
165,055
|
—
|
165,055
|
|||||||||
|
Debt securities issued by the U.S. Treasury (2)
|
748,475
|
748,475
|
—
|
|||||||||
|
Debt securities issued by states of the U.S. and political subdivisions of the states (2)
|
74,917
|
—
|
74,917
|
|||||||||
|
Other municipal debt securities (2)
|
5,994
|
—
|
5,994
|
|||||||||
|
Publicly traded equity securities included in other current assets (4)
|
10,539
|
10,539
|
—
|
|||||||||
|
Total
|
$
|
1,943,585
|
$
|
970,669
|
$
|
972,916
|
||||||
The following footnotes reference lines in our condensed consolidated balance sheets:
| (1) |
Included in cash and cash
equivalents in our condensed consolidated balance sheets.
|
| (2) |
Included in short-term
investments in our condensed consolidated balance sheets.
|
| (3) |
$1.0 million was included in cash and cash equivalents, with the difference included in short-term investments, in our condensed consolidated balance
sheets.
|
| (4) |
Included in other current assets
in our condensed consolidated balance sheets.
|
| (5) |
$11.0 million was included in cash and cash equivalents, with the difference included in short-term investments, in our condensed consolidated
balance sheets.
|
Convertible Notes
Our 1.75%
Notes, 0% Notes and 0.125% Notes had
a fair value of $605.3 million, $620.1
million and $42.4 million at September 30, 2023,
respectively. Our 0% Notes and 0.125%
Notes had a fair value of $587.3 million and $498.9
million at December 31, 2022, respectively. We determine the fair value of our notes based on quoted market prices for these notes, which are
Level 2 measurements because the notes do not trade regularly.
9. Stock-based Compensation Expense
We measure stock-based compensation expense for equity-classified awards, principally related to stock
options, RSUs, PRSUs and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense
over the requisite service period in our condensed consolidated statements of operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those
estimates. We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP.
On the grant date, we use our stock price and assumptions regarding a number of variables to determine the estimated fair
value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.
We recognize compensation expense for stock options, RSUs, PRSUs and stock purchase rights under the ESPP using the
accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as
though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.
For the nine months ended September 30, 2023 and 2022, we used the
following weighted-average assumptions in our Black-Scholes calculations:
Employee Stock Options:
|
Nine Months Ended
September 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Risk-free interest rate
|
3.7
|
%
|
1.9
|
%
|
||||
|
Dividend yield
|
0.0
|
%
|
0.0
|
%
|
||||
|
Volatility
|
47.1
|
%
|
54.9
|
%
|
||||
|
Expected life
|
6.3 years
|
6.3 years
|
||||||
Ionis Board of Director Stock Options:
|
Nine Months Ended
September 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Risk-free interest rate
|
3.8
|
%
|
2.9
|
%
|
||||
|
Dividend yield
|
0.0
|
%
|
0.0
|
%
|
||||
|
Volatility
|
53.0
|
%
|
56.2
|
%
|
||||
|
Expected life
|
7.7 years
|
7.4 years
|
||||||
ESPP:
|
Nine Months Ended
September 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Risk-free interest rate
|
5.3
|
%
|
1.2
|
%
|
||||
|
Dividend yield
|
0.0
|
%
|
0.0
|
%
|
||||
|
Volatility
|
36.0
|
%
|
50.1
|
%
|
||||
|
Expected life
|
6 months
|
6 months
|
||||||
RSUs:
The fair value of RSUs is based on the market price of our common stock on the date of grant. The RSUs we have granted to
employees vest annually over a four-year period. The RSUs we granted to our board of directors prior to June 2020 vest annually over a four-year period. The RSUs we granted after June 2020 to our board of directors fully vest after one year. The weighted-average grant date fair value of RSUs granted to employees for the nine months ended September 30, 2023 and 2022 was $39.78 and $34.88 per share, respectively.
PRSUs:
Beginning in 2020, we added PRSU awards to the compensation for our Chief Executive Officer, Dr. Brett Monia. In 2022, we added PRSU
awards to the compensation for our other Section 16 officers. Beginning in 2023, we added PRSU awards to the compensation for all executive officers.
Under the terms of the PRSUs we granted in 2020 through 2022, of the PRSUs may vest at the end of three separate performance periods
spread over the three years following the date of grant (i.e., the one-year period commencing on the date of grant and ending on the first anniversary of the date of grant, the two-year period commencing on the date of grant and ending on the second anniversary of the date of grant and the three-year period commencing on the date of grant and ending on the third anniversary of the date of grant) based on our relative total shareholder return, or TSR, as compared to a peer group of
companies, and as measured, in each case, at the end of the applicable performance period. Under the terms of the grants, no number of PRSUs is
guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero percentto 150 percent of the target number depending on our relative TSR.
Under the terms of the PRSUs we granted in 2023, 100 percent of the PRSUs may vest at the end of the three-year performance period
based on our relative TSR as compared to a peer group of companies and as measured at the end of the performance period. Under the terms of the grants, no
number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero
to 200 percent of the target number depending on our relative TSR.
We determined the fair value of the PRSUs using a Monte Carlo model because the performance target is based on our relative TSR, which
represents a market condition. The weighted-average grant date fair value of PRSUs granted to our executive officers for the nine months ended September 30, 2023 and 2022 were $58.99 and $42.28 per share, respectively.
The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2023 and 2022 (in thousands):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Cost of sales
|
$
|
118
|
$
|
163
|
$
|
355
|
$
|
376
|
||||||||
|
Research, development and patent expense
|
18,727
|
17,733
|
57,543
|
55,315
|
||||||||||||
|
Selling, general and administrative expense
|
7,119
|
5,941
|
21,575
|
18,884
|
||||||||||||
|
Total stock-based compensation expense
|
$
|
25,964
|
$
|
23,837
|
$
|
79,473
|
$
|
74,575
|
||||||||
As of September 30, 2023,
total unrecognized estimated stock-based compensation expense related to non-vested stock options, RSUs and PRSUs was $44.1 million, $62.2 million and $7.3 million, respectively. Our
actual expenses may differ from these estimates because we will adjust our unrecognized stock-based compensation expense for future forfeitures, including any PRSUs that do not vest. We expect to recognize the cost of stock-based compensation expense
related to our non-vested stock options, RSUs and PRSUs over a weighted average amortization period of 1.2 years, 1.4 years and 1.7 years, respectively.
10. Income Taxes
Beginning in 2022, the Tax Cuts and Jobs Act of 2017, or TCJA, requires taxpayers to amortize research and development
expenditures over five years pursuant to Internal Revenue Code, or IRC, Section 174. Additionally, we expect to reflect the royalty purchase agreement with Royalty Pharma as a taxable sale, requiring us to include the proceeds from the sale, net of
currently deductible issuance costs, as taxable income in 2023. The resulting tax liability is partially offset by the utilization of our R&D tax credits.
We recorded income tax expense of $6.6 million and $25.8 million for the three and nine months ended September 30, 2023, respectively, compared to $0.3 million and $3.6 million for the same periods
in 2022, respectively. The increase in income tax expense for the three and nine months ended September 30, 2023, compared to the same periods in 2022, relates primarily to the impact of the Royalty Pharma transaction.
We continue to maintain a full valuation allowance on all our net deferred tax assets.
11. Liability Related to Sale of Future Royalties
In January 2023, we entered into a royalty purchase agreement with Royalty Pharma to monetize a portion of our future
SPINRAZA and pelacarsen royalties we are entitled to under our arrangements with Biogen and Novartis, respectively. As a result, we received an upfront payment of $500 million and we are eligible to receive up to $625 million in additional milestone
payments. Under the terms of the agreement, Royalty Pharma will receive 25 percent of our SPINRAZA royalty payments from 2023 through 2027,
increasing to 45 percent of royalty payments in 2028, on up to $1.5 billion in annual sales. In addition, Royalty Pharma will receive 25 percent of
any future royalty payments on pelacarsen. Royalty Pharma’s royalty interest in SPINRAZA will revert to us after total SPINRAZA royalty payments to Royalty Pharma reach either $475 million or $550 million, depending on the timing and occurrence of FDA approval of
pelacarsen.
We recorded the upfront payment of $500 million as a liability related to the sale of future royalties, net of transaction costs of $10.4
million, which we are amortizing over the estimated life of the arrangement using the effective interest rate method. We recognize royalty revenue in the period in which the counterparty sells the related product and recognizes the related revenue. We
record royalty payments made to Royalty Pharma as a reduction of the liability.
We determine the effective interest rate used to record interest expense under this agreement based on an estimate of
future royalty payments to Royalty Pharma. As of September 30, 2023, the estimated effective interest rate under the agreement was 13.5 percent.
The following is a summary of our liability related to sale of future royalties for
the nine months ended September 30, 2023
(in thousands):
|
Proceeds from sale of future royalties
|
$
|
500,000
|
||
|
Royalty payments to Royalty Pharma
|
(27,814
|
)
|
||
|
Interest expense related to sale of future royalties
|
50,541
|
|||
|
Liability related to sale of future royalties as of September 30, 2023
|
522,727
|
|||
|
Issuance costs related to sale of future royalties
|
(10,434
|
)
|
||
|
Amortization of issuance costs related to sale of future royalties as of September 30, 2023
|
407
|
|||
|
Net liability related to sale of future royalties as of September 30, 2023
|
$
|
512,700
|
There are numerous factors, most of which are not within our control, that could materially impact the amount and timing
of royalty payments from Biogen and Novartis, and result in changes to our estimate of future royalty payments to Royalty Pharma. Such factors include, but are not limited to the commercial sales of SPINRAZA, the regulatory approval and commercial
sales of pelacarsen, competing products or other significant events.
12. Convertible Debt
1.75 Percent Convertible Senior Notes
In June 2023, we completed a $575.0
million offering of convertible senior notes and used $420.4 million of the net proceeds from the issuance of the 1.75% Notes to repurchase $434.1 million in
principal of our 0.125% Notes. In the third quarter of 2023, we used $67.8 million of the residual proceeds to repurchase an additional $70.3 million in
principal of our 0.125% Notes. We expect to use the remaining net proceeds to settle the 0.125% Notes that remain outstanding.
At September 30, 2023, we had the
following 1.75% Notes outstanding (in millions except interest rate and price per share data):
|
1.75%
Notes
|
||||
|
Outstanding principal balance
|
$
|
575.0
|
||
|
Unamortized debt issuance costs
|
$
|
13.4
|
||
|
Maturity date
|
|
|||
|
Interest rate
|
1.75 percent
|
|||
|
Effective interest rate
|
2.3 percent
|
|||
|
Conversion price per share
|
$
|
53.73
|
||
|
Total shares of common stock subject to conversion
|
10.7
|
|||
0 Percent
Convertible Senior Notes and Call Spread
In April 2021, we completed a $632.5
million offering of convertible senior notes. We used $257.0 million of the net proceeds from the issuance of the 0% Notes to repurchase $247.9 million in
principal of our 1% convertible senior notes, or 1%
Notes.
At September 30, 2023, we had the following
0% Notes outstanding (in millions except interest rate and
price per share data):
|
0% Notes
|
||||
|
Outstanding principal balance
|
$
|
632.5
|
||
|
Unamortized debt issuance costs
|
$
|
7.9
|
||
|
Maturity date
|
|
|||
|
Interest rate
|
0 percent
|
|||
|
Effective interest rate
|
0.5 percent
|
|||
|
Conversion price per share
|
$
|
57.84
|
||
|
Effective conversion price per share with call spread
|
$
|
76.39
|
||
|
Total shares of common stock subject to conversion
|
10.9
|
|||
In conjunction with the April 2021 offering, we entered into a call spread transaction, which was comprised of purchasing note hedges and
selling warrants, to minimize the impact of potential economic dilution upon conversion of our 0% Notes by increasing the effective conversion price on our 0% Notes. We increased our effective conversion price to $76.39
with the same number of underlying shares as our 0% Notes.
The call spread cost us $46.9 million, of which $136.7
million was for the note hedge purchase, offset by $89.8 million we received for selling the warrants. Similar to our 0% Notes, our note hedges are subject to adjustment. Additionally, our note hedges
are exercisable upon conversion of the 0% Notes. The note
hedges will expire upon maturity of the 0% Notes, or April
2026. The note hedges and warrants are separate transactions and are not part of the terms of our 0% Notes. The holders of the 0% Notes do not have any rights with respect to the note hedges and warrants.
We recorded the amount we paid for the note hedges and the amount we received for the warrants in additional paid-in capital in our
condensed consolidated balance sheets. Refer to Part IV, Item 15, Note 1, Organization and Significant Accounting Policies, of our audited
financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 for our Call Spread accounting policy. We
reassess our ability to continue to classify the note hedges and warrants in shareholders’ equity at each reporting period.
0.125 Percent
Convertible Senior Notes and Call Spread
As discussed above, in June 2023, we repurchased $434.1 million of our 0.125% Notes. In the third quarter of 2023, we used $67.8 million of residual net proceeds from the issuance of the 1.75%
Notes to repurchase an additional $70.3 million of our 0.125% Notes. As a result, the remaining principal balance of our 0.125% Notes was $44.5 million as of September 30, 2023.
Additionally, in the three and nine months ended September 30, 2023, we recorded a $2.1 million and $13.4 million gain on the early retirement of debt, respectively, which
we recorded as other income in our condensed consolidated statements of operations. The gain on the early retirement of our debt is the difference between the amounts paid to repurchase our 0.125% Notes and the net carrying balance of the liability at the time that we completed the repurchases.
At September 30, 2023, we had the
following 0.125% Notes outstanding with interest payable semi-annually (in millions except interest rate and price per share data):
|
0.125%
Notes
|
||||
|
Outstanding principal balance
|
$
|
44.5
|
||
|
Unamortized debt issuance costs
|
$
|
0.2
|
||
|
Maturity date
|
|
|||
|
Interest rate
|
0.125 percent
|
|||
|
Effective interest rate
|
0.5 percent
|
|||
|
Conversion price per share
|
$
|
83.28
|
||
|
Effective conversion price per share with call spread
|
$
|
123.38
|
||
|
Total shares of common stock subject to conversion
|
0.5
|
|||
In conjunction with the issuance of our 0.125% Notes in December 2019, we entered into a call spread
transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our 0.125% Notes by increasing the effective conversion price on our 0.125% Notes. We increased our effective conversion price to $123.38 with the same number of underlying shares as our 0.125% Notes. The call spread cost us $52.6 million, of which $108.7 million was for the note hedge purchase, offset by $56.1 million we received for selling the warrants. Similar to our 0.125%
Notes, our note hedges are subject to adjustment. Additionally, our note hedges are exercisable upon conversion of the 0.125% Notes. The note hedges will expire upon maturity of the
0.125% Notes, or December 2024. The note
hedges and warrants are separate transactions and are not part of the terms of our 0.125% Notes. The holders of the 0.125% Notes do not have any rights with respect to the note hedges and warrants. As of September 30, 2023, the note hedges and warrants remain outstanding.
We recorded the amount we paid for the note hedges and the amount we received for the warrants in additional paid-in
capital in our condensed consolidated balance sheets. We reassess our ability to continue to classify the note hedges and warrants in shareholders’ equity at each reporting period.
Other Terms of Convertible Senior Notes
The 1.75%, 0% and 0.125% Notes are convertible under certain conditions, at the
option of the note holders. We can settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the notes prior to maturity, and we do not have to provide a sinking fund for them.
Holders of the notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indentures governing the notes, at a purchase price equal to 100 percent of the principal amount of the notes to be
purchased, plus any accrued and unpaid interest.
13. Real Estate Transactions
In October 2022, we concurrently entered into two purchase and sale agreements with a real estate investor. In the same month, we closed the first transaction in which we sold the facilities at our headquarters in Carlsbad, California,
which includes our primary R&D facility, for a purchase price of $263.4 million. In connection with this transaction, we leased back our
headquarters facilities for an initial lease term of 15 years with options to extend the lease for two additional terms of five years each.
In August 2023, we closed the second transaction and transferred legal ownership of two lots of undeveloped land adjacent to our headquarters to the real estate investor for a purchase price of $33 million. In connection with this transaction, we entered into a build-to-suit lease agreement with the same real estate investor to lease a new R&D facility. The lessor will develop and
construct a new building composed of R&D and office space. We will design and construct tenant improvements to customize the facility’s interior space. We will lease the facility for an initial term of 15 years with options to extend the lease for two additional terms of five years each. The lease will commence once the structure of this new facility is completed.
Since the building is under construction and unavailable to lease, we are unable to complete the sale-leaseback evaluation under ASC 842,
Leases. As a result, the land remains in our condensed consolidated balance sheets and we accounted for the proceeds as a financial liability. We
will reassess the transaction under the sale-leaseback accounting guidance when the facilities are available for lease commencement.
In October 2022, we entered into a build-to-suit lease agreement to lease a development chemistry and manufacturing facility to be
constructed by the lessor in Oceanside, California. We capitalized costs that we incurred related to the design and development of tenant improvements as construction-in-progress in our condensed consolidated balance sheets. In August 2023, we reached
a mutual agreement with the lessor to terminate the lease agreement. As a result, we recorded a charge of $18 million, primarily associated with
the impairment of construction-in-progress assets, within , or SG&A, expense in our condensed
consolidated statements of operations.
14. Legal Proceedings
From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we
evaluate the status of each legal matter and assess our potential financial exposure. If we consider the potential loss from any legal proceeding to be probable and we can reasonably estimate the amount, we accrue a liability for the estimated loss.
The outcome of any proceeding is not determinable in advance. Therefore, we are required to use significant judgment to determine the probability of a loss and whether the amount of the loss is reasonably estimable. Our assessment of a potential
liability and the amount of accruals we recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding and may revise our
estimates.
There are no pending material legal proceedings to which we are a party or of which our property is the subject.
In this Report on Form 10-Q, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,”
and “us,” means Ionis Pharmaceuticals, Inc. and its wholly owned subsidiary, Akcea Therapeutics, Inc.
Forward-Looking Statements
In addition to historical information contained in this Report on Form 10-Q, the Report includes
forward-looking statements regarding our business and the therapeutic and commercial potential of QALSODY (tofersen), SPINRAZA (nusinersen), TEGSEDI (inotersen), WAYLIVRA (volanesorsen), eplontersen, olezarsen, donidalorsen, zilganersen, ulefnersen
(ION363), pelacarsen, bepirovirsen, IONIS-FB-LRx, our technologies and our other products in development. Any statement describing our goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around such medicines. Our forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause our results to differ materially from those expressed
or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this report and described in additional detail in our annual report on Form 10-K for the year
ended December 31, 2022, which is on file with the U.S. Securities and Exchange Commission and is available from us, and those identified
within Part II Item 1A. Risk Factors of this Report. Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, you are cautioned
not to rely on these forward-looking statements.
We were founded over 30 years ago to deliver innovative medicines for diseases with great medical need. Today, we are
building on our advancements in RNA-targeted therapeutics to deliver our medicines to the market that have the potential to transform the lives of people with devastating diseases. We currently have four marketed medicines: QALSODY, SPINRAZA, TEGSEDI
and WAYLIVRA. On April 25, 2023, the U.S. Food and Drug Administration, or FDA, granted Biogen accelerated approval of QALSODY for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis, or SOD1-ALS. Additionally, the FDA accepted our
New Drug Application, or NDA, of eplontersen for polyneuropathy caused by hereditary TTR amyloidosis, or ATTRv-PN. eplontersen’s Prescription Drug User Fee Act, or PDUFA, date is December 22, 2023. We also have a rich innovative late- and mid-stage
pipeline primarily focused on our leading cardiovascular and neurology franchises. In the first nine months of 2023, we expanded our late-stage pipeline with the initiations of Roche’s Phase 3 study of IONIS-FB-LRx in patients with
immunoglobulin A nephropathy, or IgAN, and GSK’s Phase 3 program of bepirovirsen. In addition, we recently advanced zilganersen, our wholly owned medicine for the treatment of Alexander disease, or AxD, into the Phase 3 portion of our ongoing study. In
September 2023, we reported positive data from the Phase 3 Balance study of olezarsen in patients with familial chylomicronemia syndrome, or FCS, showing dose-dependent reductions in APOCIII, statistically significant reductions in triglycerides, and
substantial reductions in acute pancreatitis attacks and a favorable safety and tolerability profile. Based on these results, we plan to file for regulatory approval with the U.S. FDA and with the European Medicines Agency, or EMA, in 2024.
We believe our substantial and sustainable revenue and strong balance sheet enable us to continue investing in our
commercial readiness efforts for multiple late-stage medicines and our innovative pipeline. By continuing to focus on these priorities, we believe we are well positioned to drive future growth and to deliver increasing value for patients and
shareholders.
Marketed Medicines
SPINRAZA is the global market leader for the
treatment of patients with spinal muscular atrophy, or SMA, a progressive, debilitating and often fatal genetic disease. Our partner, Biogen, is responsible for commercializing SPINRAZA worldwide. From inception through September 30, 2023, we have earned more than $2.0
billion in revenues from our SPINRAZA collaboration, including more than $1.6 billion in royalties on sales of SPINRAZA.
TEGSEDI is a once weekly, self-administered subcutaneous medicine approved in the U.S., Europe, Canada and Brazil for the
treatment of patients with ATTRv-PN, a debilitating, progressive, and fatal disease. We launched TEGSEDI in the United States, or U.S., and the European Union, or EU, in late 2018. In 2021, we began selling TEGSEDI in Europe through our distribution
agreement with Swedish Orphan Biovitrum AB, or Sobi, and in the second quarter of 2021, Sobi began distributing TEGSEDI in the U.S. and Canada. In October 2023, our distribution agreement for TEGSEDI in North America was terminated. In Latin America,
PTC Therapeutics International Limited, or PTC, is commercializing TEGSEDI in Brazil and is pursuing access in additional Latin American countries through its exclusive license agreement with us.
WAYLIVRA is a once weekly, self-administered, subcutaneous medicine that received conditional marketing authorization in
May 2019 from the European Commission, or EC, as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis. We launched WAYLIVRA in the EU in the third quarter of 2019. In 2021, we began selling WAYLIVRA in
Europe through our distribution agreement with Sobi. In Latin America, PTC is commercializing WAYLIVRA in Brazil for two indications, FCS and familial partial lipodystrophy, or FPL, and is pursuing access in additional Latin American countries through
its exclusive license agreement with us.
QALSODY is an antisense medicine that received accelerated approval in April 2023 from the FDA for the treatment of adult
patients with SOD1-ALS, a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. Our partner, Biogen, is responsible for commercializing QALSODY worldwide. The EMA is currently reviewing QALSODY for approval in
the EU.
Medicines in Registration and Phase 3 Studies
We currently have nine medicines in Phase 3 studies for eleven indications, which include:
| ● |
Eplontersen: our medicine in development for transthyretin amyloidosis, or
ATTR
|
| o |
We are currently conducting a broad Phase 3 development program for ATTRv-PN and ATTR cardiomyopathy, or ATTR-CM, and additional studies supporting our
ATTR development program
|
| ● |
The FDA accepted the NDA of eplontersen in the U.S. for ATTRv-PN with a PDUFA
date of December 22, 2023, and eplontersen is currently under regulatory review by the EMA and Health Canada for ATTRv-PN
|
| ● |
In November 2023, we presented new positive data showing continued benefit in secondary endpoints from the Phase 3 NEURO-TTRansform study in patients with ATTRv-PN at
EU-ATTR congress
|
| ● |
In October 2023, the EMA granted orphan drug designation to eplontersen for the treatment of ATTR in the EU
|
| ● |
In September 2023, The Journal of the American Medical Association
(JAMA) published positive results from the Phase 3 NEURO-TTRansform study in patients with ATTRv-PN showing eplontersen halted disease
progression and continuously improved quality of life at 35-, 66- and 85-week analyses
|
| ● |
In July 2023, we completed enrollment of the Phase 3 CARDIO-TTRansform study of eplontersen in patients with ATTR-CM
|
| ● |
Olezarsen: our medicine in development for FCS and severe hypertriglyceridemia, or SHTG
|
| o |
We are currently conducting a broad Phase 3 development program for olezarsen that includes the Phase 3 Balance study in patients with FCS, three Phase 3
studies supporting development for the treatment of SHTG (CORE, CORE2 and ESSENCE) and a Phase 2b supporting study
|
| ● |
In September 2023, we reported positive results from the Phase 3 Balance
study in patients with FCS showing statistically significant triglyceride lowering and a substantial reduction in acute pancreatitis events in addition to a favorable safety and tolerability profile
|
| ● |
In January 2023, the FDA granted fast track designation to olezarsen for the
treatment of patients with FCS
|
| ● |
Donidalorsen: our medicine in development for hereditary angioedema, or HAE
|
| o |
We are currently conducting the Phase 3 OASIS-HAE study in patients with HAE and the Phase 3 OASIS-Plus supportive study for HAE patients previously
treated with other prophylactic therapies
|
| ● |
In September 2023, the FDA granted orphan drug designation to donidalorsen for the treatment of HAE
|
| ● |
In June 2023, we completed enrollment of the Phase 3 OASIS-HAE study of donidalorsen in patients with hereditary angioedema; we remain on track for data in the first half
of 2024
|
| ● |
We reported positive data from the Phase 2 study and Phase 2 open-label extension, or OLE, study throughout 2022 and early 2023, including new topline two-year OLE data in June 2023
|
| ● |
Ulefnersen (ION363): our medicine in development for amyotrophic lateral sclerosis, or ALS, with mutations in the fused in sarcoma gene, or FUS
|
| o |
We are currently conducting a Phase 3 study of ulefnersen in juvenile and adult patients with FUS-ALS
|
| ● |
In August 2023, the FDA granted orphan drug designation to ulefnersen for the treatment of FUS-ALS
|
| ● |
QALSODY: our medicine to treat patients with SOD1-ALS that is approved in the U.S., under regulatory review in the EU and in development for presymptomatic patients
|
| o |
In April 2023, the FDA granted Biogen accelerated approval of QALSODY
for patients with SOD1-ALS
|
| o |
The EMA is currently reviewing QALSODY’s Marketing Authorization
Application, or MAA, in the EU
|
| ● |
Pelacarsen: our medicine in development to treat patients with elevated
lipoprotein(a), or Lp(a)-driven cardiovascular disease, or CVD
|
| o |
Novartis is developing pelacarsen, including conducting the ongoing Lp(a) HORIZON Phase 3 cardiovascular outcome study in patients with elevated
Lp(a)-driven CVD
|
| ● |
In July 2022, Novartis achieved full enrollment in the Lp(a) HORIZON study
|
| ● |
Bepirovirsen: our medicine in development for hepatitis B virus, or HBV
|
| o |
GSK is developing bepirovirsen, including conducting the ongoing B-Well Phase 3 program in patients with HBV
|
| ● |
In October 2023, GSK reported positive results from the Phase 2b B-Together study followed by pegylated interferon in patients with chronic HBV
|
| ● |
In June 2023, GSK presented durable response data from the Phase 2 B-Sure
long-term follow-up study of bepirovirsen in complete responder patients from the Phase 2b B-Clear study of patients with HBV
|
| ● |
IONIS-FB-LRx: our medicine in development for IgAN and geographic atrophy, or GA
|
| o |
In the second quarter of 2023, Roche advanced IONIS-FB-LRx into Phase 3
development in patients with IgAN
|
| o |
In October 2023, we reported positive interim data from the ongoing Phase 2
study of IONIS-FB-LRx in patients with IgAN
|
| o |
In June 2023, we completed enrollment in the Phase 2 GOLDEN study of IONIS-FB-LRx in patients with GA
|
| ● |
Zilganersen: our medicine in development for AxD
|
| o |
In September 2023, we advanced zilganersen into the Phase 3 portion of its ongoing study for patients with AxD
|
We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. As
such, we make certain estimates, judgments and assumptions that we believe are reasonable, based upon the information available to us. These judgments involve making estimates about the effect of matters that are inherently uncertain and may
significantly impact our quarterly or annual results of operations and financial condition. Each quarter, our senior management reviews the development, selection and disclosure of such estimates with the audit committee of our board of directors. The
following are our significant accounting estimates, which we believe are the most critical to aid in fully understanding and evaluating our reported financial results:
| ● |
Assessing the propriety of revenue recognition and associated deferred revenue; and
|
| ● |
Determining the appropriate cost estimates for unbilled preclinical studies and clinical development activities
|
There have been no other material changes to our critical accounting policies and estimates from the information provided
in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form
10-K for the year ended December 31, 2022.
The following is a summary of our financial results (in millions):
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
September 30,
|
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Total revenue
|
$
|
144.2
|
$
|
159.8
|
$
|
463.1
|
$
|
435.5
|
||||||||
|
Total operating expenses
|
$
|
287.5
|
$
|
218.9
|
$
|
810.7
|
$
|
637.7
|
||||||||
|
Loss from operations
|
$
|
(143.3
|
)
|
$
|
(59.2
|
)
|
$
|
(347.6
|
)
|
$
|
(202.2
|
)
|
||||
|
Net loss
|
$
|
(147.4
|
)
|
$
|
(47.0
|
)
|
$
|
(357.0
|
)
|
$
|
(217.3
|
)
|
||||
Revenue
Total revenues for the three and nine months ended September 30, 2023 were $144.2 million and $463.1 million, respectively, compared to $159.8 million and $435.5 million for the same periods in 2022 and were comprised of the following (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Revenue:
|
||||||||||||||||
|
Commercial revenue:
|
||||||||||||||||
|
SPINRAZA royalties
|
$
|
67.3
|
$
|
61.6
|
$
|
178.5
|
$
|
175.1
|
||||||||
|
Other commercial revenue:
|
||||||||||||||||
|
TEGSEDI and WAYLIVRA revenue, net
|
8.3
|
5.9
|
25.4
|
22.5
|
||||||||||||
|
Licensing and other royalty revenue
|
8.5
|
4.9
|
25.8
|
25.3
|
||||||||||||
|
Total other commercial revenue
|
16.8
|
10.8
|
51.2
|
47.8
|
||||||||||||
|
Total commercial revenue
|
84.1
|
72.4
|
229.7
|
222.9
|
||||||||||||
|
R&D revenue:
|
||||||||||||||||
|
Amortization from upfront payments
|
18.0
|
18.1
|
46.8
|
54.0
|
||||||||||||
|
Milestone payments
|
16.2
|
14.9
|
89.8
|
59.7
|
||||||||||||
|
License fees
|
4.6
|
35.0
|
24.6
|
37.0
|
||||||||||||
|
Other services
|
5.3
|
1.3
|
12.3
|
6.6
|
||||||||||||
|
Collaborative agreement revenue
|
44.1
|
69.3
|
173.5
|
157.3
|
||||||||||||
|
Eplontersen joint development revenue
|
16.0
|
18.1
|
59.9
|
55.3
|
||||||||||||
|
Total R&D revenue
|
60.1
|
87.4
|
233.4
|
212.6
|
||||||||||||
|
Total revenue
|
$
|
144.2
|
$
|
159.8
|
$
|
463.1
|
$
|
435.5
|
||||||||
Commercial revenue for the three and nine months ended September 30, 2023 included $67 million and $179 million from
SPINRAZA royalties, respectively, which were relatively consistent compared to the same periods in 2022. Our commercial revenue in the three and nine months ended September 30, 2023 also included royalties from the U.S. launch of QALSODY.
R&D revenue decreased for three months ended September 30, 2023 and increased for the nine months ended September 30,
2023 compared to the same periods in 2022 due to the timing of certain partner payments. The decrease for the three months comparison was due to the $35 million license fee for IONIS-FB-LRx that we earned from Roche in the three months ended
September 30, 2022. The increase for the nine months comparison was driven by increased partner payments in 2023 compared to 2022.
Eplontersen Collaboration with AstraZeneca
Our financial results for the three and nine months ended September 30, 2023 and 2022 reflected the cost-sharing provisions related to our collaboration with AstraZeneca to develop and commercialize eplontersen for the treatment of ATTR. Under the terms of
the collaboration agreement, AstraZeneca is currently paying 55 percent of the costs associated with the ongoing global Phase 3 development program. Because we are leading and conducting the Phase 3 development program, we are recognizing as R&D
revenue the 55 percent of cost-share funding AstraZeneca is responsible for, net of our share of AstraZeneca’s development expenses, in the same period we incur the related development expenses.
As AstraZeneca is responsible for the majority of the medical affairs and commercial costs in the U.S. and all costs
associated with bringing eplontersen to market outside the U.S., we are recognizing cost-share funding we receive from AstraZeneca related to these activities as a reduction of our medical affairs and commercialization expenses, which we classify as
R&D and selling, general and administrative, or SG&A, expenses, respectively. We expect our medical affairs and commercialization expenses to increase as eplontersen advances toward the market under our collaboration with AstraZeneca.
Our revenue and expenses under this collaboration were as follows (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Eplontersen joint development revenue
|
$
|
16.0
|
$
|
18.1
|
$
|
59.9
|
$
|
55.3
|
||||||||
|
Research and development expenses related to Phase 3 development expenses for eplontersen
|
32.4
|
36.2
|
117.8
|
107.3
|
||||||||||||
|
Medical affairs expenses for eplontersen
|
1.1
|
0.5
|
2.9
|
1.4
|
||||||||||||
|
Commercialization expenses for eplontersen
|
4.5
|
0.8
|
8.3
|
1.5
|
||||||||||||
Operating Expenses
Our operating expenses were as follows (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Operating expenses, excluding non-cash compensation expense related to equity awards
|
$
|
261.6
|
$
|
195.1
|
$
|
731.3
|
$
|
563.1
|
||||||||
|
Non-cash compensation expense related to equity awards
|
25.9
|
23.8
|
79.4
|
74.6
|
||||||||||||
|
Total operating expenses
|
$
|
287.5
|
$
|
218.9
|
$
|
810.7
|
$
|
637.7
|
||||||||
Operating expenses, excluding non-cash compensation expense related to equity awards, for the three and nine months ended September 30,
2023 increased compared to the same periods in 2022. Our R&D expenses increased as we advanced our pipeline, which included an increase in the costs associated with our clinical studies as most of our Phase 3 studies were either fully enrolled or
approaching full enrollment at the end of September 2023. Our SG&A expenses increased due to expenses related to our launch preparation activities for eplontersen, olezarsen and donidalorsen. We expect our operating expenses, excluding non-cash compensation expense related to equity awards, to slightly increase in the fourth quarter of 2023 as we continue to advance our late-stage
medicines in development and prepare for commercialization.
To analyze and compare our results of operations to other similar companies, we believe it is important to exclude
non-cash compensation expense related to equity awards from our operating expenses. We believe non-cash compensation expense related to equity awards is not indicative of our operating results or cash flows from our operations. Further, we internally
evaluate the performance of our operations excluding it.
Cost of Sales
Our cost of sales is comprised of costs related to our commercial revenue, which consisted of manufacturing costs,
including certain fixed costs, transportation and freight, indirect overhead costs associated with the manufacturing and distribution of TEGSEDI and WAYLIVRA and certain associated period costs.
Our cost of sales were as follows (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Cost of sales, excluding non-cash compensation expense related to equity awards
|
$
|
2.1
|
$
|
1.3
|
$
|
5.8
|
$
|
9.9
|
||||||||
|
Non-cash compensation expense related to equity awards
|
0.1
|
0.2
|
0.3
|
0.5
|
||||||||||||
|
Total cost of sales
|
$
|
2.2
|
$
|
1.5
|
$
|
6.1
|
$
|
10.4
|
||||||||
Research, Development and Patent Expenses
Our research, development and patent expenses consist of expenses for drug discovery, drug development, manufacturing and
development chemistry and R&D support expenses.
The following table sets forth information on research, development and patent expenses (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Research, development and patent expenses, excluding non-cash compensation expense related to
equity awards
|
$
|
196.5
|
$
|
165.3
|
$
|
585.5
|
$
|
469.6
|
||||||||
|
Non-cash compensation expense related to equity awards
|
18.8
|
17.7
|
57.6
|
55.3
|
||||||||||||
|
Total research, development and patent expenses
|
$
|
215.3
|
$
|
183.0
|
$
|
643.1
|
$
|
524.9
|
||||||||
Drug Discovery
We use our proprietary technologies to generate information about the function of genes and to determine the value of
genes as drug discovery targets. We use this information to direct our own drug discovery research, and that of our partners. Drug discovery is also the function that is responsible for advancing our core technology. This function is also responsible
for making investments in complementary technologies to expand the reach of our technologies.
Our drug discovery expenses were as follows (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Drug discovery expenses, excluding non-cash compensation expense related to equity awards
|
$
|
26.6
|
$
|
25.0
|
$
|
78.8
|
$
|
68.6
|
||||||||
|
Non-cash compensation expense related to equity awards
|
4.0
|
4.2
|
11.9
|
12.8
|
||||||||||||
|
Total drug discovery expenses
|
$
|
30.6
|
$
|
29.2
|
$
|
90.7
|
$
|
81.4
|
||||||||
Drug discovery expenses, excluding
non-cash compensation expense related to equity awards, increased in the three and nine months ended September 30, 2023 compared to the same periods in 2022 as
we continued to advance our research programs.
Drug Development
The following table sets forth drug development expenses, including expenses for our marketed medicines and those in
Phase 3 development for which we have incurred significant costs (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
TEGSEDI and WAYLIVRA
|
$
|
3.0
|
$
|
3.9
|
$
|
5.6
|
$
|
9.4
|
||||||||
|
Eplontersen
|
25.1
|
24.5
|
90.8
|
75.8
|
||||||||||||
|
Olezarsen
|
38.5
|
18.3
|
96.6
|
39.7
|
||||||||||||
|
Donidalorsen
|
6.9
|
5.5
|
19.4
|
9.1
|
||||||||||||
|
Ulefnersen
|
2.5
|
2.3
|
7.7
|
5.8
|
||||||||||||
|
Other development projects
|
28.2
|
31.6
|
81.4
|
91.7
|
||||||||||||
|
Development overhead expenses
|
28.3
|
22.5
|
83.8
|
63.3
|
||||||||||||
|
Total drug development, excluding non-cash compensation expense related to equity awards
|
132.5
|
108.6
|
385.3
|
294.8
|
||||||||||||
|
Non-cash compensation expense related to equity awards
|
8.6
|
7.6
|
25.7
|
15.6
|
||||||||||||
|
Total drug development expenses
|
$
|
141.1
|
$
|
116.2
|
$
|
411.0
|
$
|
310.4
|
||||||||
Our development expenses, excluding
non-cash compensation expense related to equity awards, increased for the three and nine months ended September 30, 2023 compared to the same periods in 2022
primarily due to our advancing late-stage pipeline and full or nearly full enrollment of multiple Phase 3 studies.
We may conduct multiple clinical trials on a drug candidate, including multiple clinical trials for the various
indications we may be studying. Furthermore, as we obtain results from trials, we may elect to discontinue clinical trials for certain drug candidates in certain indications in order to focus our resources on more promising drug candidates or
indications. Our Phase 1 and Phase 2 programs are clinical research programs that fuel our Phase 3 pipeline. When our medicines are in Phase 1 or Phase 2 clinical trials, they are in a dynamic state in which we may adjust the development strategy for
each medicine. Although we may characterize a medicine as “in Phase 1” or “in Phase 2,” it does not mean that we are conducting a single, well-defined study with dedicated resources. Instead, we allocate our internal resources on a shared basis across
numerous medicines based on each medicine’s particular needs at that time. This means we are constantly shifting resources among medicines. Therefore, what we spend on each medicine during a particular period is usually a function of what is required
to keep the medicines progressing in clinical development, not what medicines we think are most important. For example, the number of people required to start a new study is large, the number of people required to keep a study going is modest and the
number of people required to finish a study is large. However, such fluctuations are not indicative of a shift in our emphasis from one medicine to another and cannot be used to accurately predict future costs for each medicine. Because we always have
numerous medicines in preclinical and varying stages of clinical research, the fluctuations in expenses from medicine to medicine, in large part, offset one another. If we partner a medicine, it may affect the size of a trial, its timing, its total
cost and the timing of the related costs.
Medical Affairs
Our medical affairs function is responsible for funding and coordinating investigator-sponsored trials, communicating
scientific and clinical information to healthcare providers, medical professionals and patients, and managing publications.
Our medical affairs expenses were as follows (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Medical affairs expenses, excluding non-cash compensation expense related to equity awards
|
$
|
4.9
|
$
|
3.8
|
$
|
13.8
|
$
|
11.4
|
||||||||
|
Non-cash compensation expense related to equity awards
|
0.8
|
0.6
|
2.7
|
1.3
|
||||||||||||
|
Total medical affairs expenses
|
$
|
5.7
|
$
|
4.4
|
$
|
16.5
|
$
|
12.7
|
||||||||
Medical affairs expenses, excluding
non-cash compensation expense related to equity awards, increased in the three and nine months ended September 30, 2023 compared to the same periods in 2022. We expect medical affairs expenses, excluding non-cash compensation expense related to equity awards, to increase in the fourth quarter of 2023 as we advance our late-stage pipeline.
Manufacturing and Development Chemistry
Expenditures in our manufacturing and development chemistry function consist primarily of personnel costs, specialized
chemicals for oligonucleotide manufacturing, validation batches to support regulatory approvals, laboratory supplies and outside services. Our manufacturing and development chemistry function is responsible for providing drug supplies to drug
development and our collaboration partners. Our manufacturing procedures include testing to satisfy good laboratory and good manufacturing practice requirements.
Our manufacturing and development chemistry expenses were as follows (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Manufacturing and development chemistry expenses, excluding non-cash compensation expense related
to equity awards
|
$
|
12.3
|
$
|
14.0
|
$
|
49.2
|
$
|
53.4
|
||||||||
|
Non-cash compensation expense related to equity awards
|
2.2
|
2.3
|
6.5
|
7.6
|
||||||||||||
|
Total manufacturing and development chemistry expenses
|
$
|
14.5
|
$
|
16.3
|
$
|
55.7
|
$
|
61.0
|
||||||||
R&D Support
In our research, development and patent expenses, we include support costs such as rent, repair and maintenance for
buildings and equipment, utilities, depreciation of laboratory equipment and facilities, amortization of our intellectual property, information technology costs, procurement costs and waste disposal costs. We call these costs R&D support expenses.
The following table sets forth information on R&D support expenses (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Personnel costs
|
$
|
6.2
|
$
|
5.3
|
$
|
19.4
|
$
|
15.4
|
||||||||
|
Occupancy
|
7.2
|
4.1
|
21.4
|
12.3
|
||||||||||||
|
Patent expenses
|
0.9
|
0.9
|
2.8
|
3.1
|
||||||||||||
|
Insurance
|
0.9
|
1.0
|
2.7
|
2.8
|
||||||||||||
|
Computer software and licenses
|
0.8
|
0.1
|
2.0
|
1.1
|
||||||||||||
|
Other
|
4.2
|
2.5
|
10.1
|
6.7
|
||||||||||||
|
Total R&D support expenses, excluding non-cash compensation expense related to equity awards
|
20.2
|
13.9
|
58.4
|
41.4
|
||||||||||||
|
Non-cash compensation expense related to equity awards
|
3.2
|
3.0
|
10.8
|
10.4
|
||||||||||||
|
Total R&D support expenses
|
$
|
23.4
|
$
|
16.9
|
$
|
69.2
|
$
|
51.8
|
||||||||
R&D support expenses, excluding
non-cash compensation expense related to equity awards, increased in the three and nine months ended September 30, 2023 compared to the same periods in 2022.
The increase was primarily related to increased occupancy and personnel costs to support advancing our pipeline and our technology. In October 2022, we executed a sale and leaseback transaction for our headquarters in Carlsbad, California. As a
result, beginning in the fourth quarter of 2022, our occupancy costs increased because we began incurring rent expense for these facilities.
Selling, General and Administrative Expenses
SG&A expenses include personnel and outside costs associated with the pre-commercialization and commercialization
activities for our medicines and costs to support our company, our employees and our stockholders including, legal, human resources, investor relations and finance. Additionally, we include in selling, general and administrative expenses such costs as
rent, repair and maintenance of buildings and equipment, depreciation and utilities costs that we need to support the corporate functions listed above. We also include fees we owe under our in-licensing agreements related to SPINRAZA and QALSODY.
The following table sets forth information on SG&A expenses (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Selling, general and administrative expenses, excluding non-cash compensation expense related to
equity awards
|
$
|
62.9
|
$
|
28.5
|
$
|
140.0
|
$
|
83.6
|
||||||||
|
Non-cash compensation expense related to equity awards
|
7.1
|
5.9
|
21.6
|
18.8
|
||||||||||||
|
Total selling, general and administrative expenses
|
$
|
70.0
|
$
|
34.4
|
$
|
161.6
|
$
|
102.4
|
||||||||
SG&A expenses, excluding non-cash
compensation expense related to equity awards, increased in the three and nine months ended September 30, 2023 compared to the same periods in 2022 due
to increased expenses related to our go-to-market activities for eplontersen, olezarsen and donidalorsen. In addition, we recorded a one-time expense of $18 million when we terminated a build-to-suit lease agreement in August 2023. Refer to Part I, Item 1, Note 13, Real Estate Transactions, in the Notes to our condensed consolidated financial statements for further details on the lease termination.
Investment Income
The following table sets forth information on investment income (in millions):
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Investment income
|
$
|
23.9
|
$
|
7.5
|
$
|
63.4
|
$
|
13.4
|
||||||||
Our investment income increased primarily due to an increase in interest rates associated with our investments in debt
securities and an increase in our cash available for investment during the three and nine months ended September 30, 2023 compared to the same periods in 2022. Our cash balance increased due to the $500 million upfront payment we received in January
2023 from our royalty purchase agreement with Royalty Pharma Investments, or Royalty Pharma, and net proceeds we received from the debt offering in June 2023. These increases were partially offset by the repurchase of $504 million in principal of our
0.125% Notes during the nine months ended September 30, 2023.
Interest Expense
The following table sets forth information on interest expense (in millions):
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Convertible notes:
|
||||||||||||||||
|
Non-cash amortization of debt issuance costs
|
$
|
1.6
|
$
|
1.3
|
$
|
4.3
|
$
|
4.0
|
||||||||
|
Interest expense payable in cash
|
2.5
|
0.2
|
3.5
|
0.5
|
||||||||||||
|
Interest on mortgage for primary R&D and manufacturing facilities
|
0.1
|
0.6
|
0.3
|
1.9
|
||||||||||||
|
Total interest expense
|
$
|
4.2
|
$
|
2.1
|
$
|
8.1
|
$
|
6.4
|
||||||||
In June 2023, we completed a $575.0 million offering of our 1.75% Notes and repurchased $434.1 million in principal of our
0.125% Notes. As a result, beginning in the second quarter of 2023, our interest expense related to our convertible notes increased because we began incurring interest expense for our 1.75% Notes.
Interest Expense Related to Sale of Future Royalties
We recorded $17.8 million and $50.9 million of interest expense related to the sale of future royalties in the three
and nine months ended September 30, 2023, respectively, as a result of the Royalty
Pharma transaction, in which we sold a minority interest in our future royalties to Royalty Pharma for a $500 million upfront payment and $625 million of potential future payments. Refer to Part I, Item 1, Note 11, Liability Related to Sale of Future Royalties, in the Notes to our condensed consolidated financial statements for further details.
Gain (Loss) on Investments
The following table sets forth information on gain (loss) on investments (in millions):
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
|||||||||||||
|
Gain (loss) on investments
|
$
|
(1.9
|
)
|
$
|
2.3
|
$
|
(1.8
|
)
|
$
|
(10.6
|
)
|
|||||
The period-over-period fluctuations in our gain (loss) on investments were driven by changes in the fair value of our
investments in privately held and publicly traded biotechnology companies. The loss on investments in the nine months ended September 30, 2022 was primarily driven by losses on our investments in publicly traded biotechnology companies.
Other Expense
In June 2023, we completed a $575.0 million offering of our 1.75% Notes and used $420.4 million of the net proceeds to repurchase $434.1
million in principal of our 0.125% Notes. In the third quarter of 2023, we used $67.8 of the residual proceeds to repurchase an additional $70.3 million in principal of our 0.125% Notes. As a result of these repurchases, we recorded a $13.4 million
gain on early retirement of debt for the nine months ended September 30, 2023, which reflects the difference between the amounts we paid to repurchase portions of our 0.125% Notes and the net carrying balance of the liability at the time that we
repurchased the debt. Refer to Part I, Item 1, Note 12, Convertible Debt, in the Notes to our condensed consolidated financial statements for
further details regarding our convertible debt.
In the second quarter of 2022, we recorded a non-operating expense of $12.5 million related to a settlement agreement for a litigation
claim. Refer to Part IV, Item 15, Note 9, Legal Proceedings, of our audited financial statements included in our Annual Report on Form 10-K for the
year ended December 31, 2022 for further details regarding the litigation.
Income Tax Expense
Beginning in 2022, the Tax Cuts and Jobs Act of 2017, or TCJA, requires taxpayers to amortize research and development
expenditures over five years pursuant to Internal Revenue Code, or IRC, Section 174. Additionally, we expect to reflect the royalty purchase agreement with Royalty Pharma as a taxable sale, requiring us to include the proceeds from the sale, net of
currently deductible issuance costs, as taxable income in 2023. The resulting tax liability is partially offset by the utilization of our R&D tax credits.
We recorded income tax expense of $6.6 million and $25.8 million for the three and nine months ended September 30, 2023, respectively, compared to $0.3 million and $3.6 million for the same periods
in 2022, respectively. The increase in income tax expense for the three and nine months ended September 30, 2023, compared to the same periods in 2022, relates primarily to the impact of the Royalty Pharma transaction.
We continue to maintain a full valuation allowance on all our net deferred tax assets.
Net Loss and Net Loss per Share
We had a net loss of $147.4
million and $357.0 million for the three and nine months ended September 30, 2023,
respectively. We had a net loss of $47.0 million and $217.3 million for the same periods in 2022. The period-over-period fluctuations in our net loss were driven by factors discussed in the sections above. Basic and diluted net loss per share for the three and nine months ended September 30, 2023 were $1.03 and $2.50, respectively,
compared to $0.33 and $1.53 for the same periods in 2022.
We have financed our operations primarily
from research and development collaborative agreements. We also finance our operations from commercial revenue from royalties, most notably from SPINRAZA, and TEGSEDI and WAYLIVRA commercial revenue. From our inception through September 30, 2023, we have earned approximately $6.9 billion in revenue. We have also financed our operations through
the sale of our equity securities, the issuance of long-term debt and the sale of future royalties. From the time we were founded through September 30, 2023, we have raised net proceeds of approximately $2.1 billion from the sale of our equity securities. Additionally, from our inception through September 30, 2023, we have borrowed approximately $2.7 billion under long-term debt arrangements and received proceeds of $0.5 billion from the sale of future royalties to finance a portion of our
operations.
Our cash, cash equivalents and short-term
investments, working capital and long-term obligations increased from December 31, 2022 to September 30, 2023. As discussed above, in the nine months ended September 30,
2023, we repurchased $504.4 million in principal of our 0.125% Notes. In the third quarter of 2023, we closed a real estate transaction for a total purchase price of $33.0 million. In the second quarter of 2023, we issued $575.0 million of 1.75% Notes
(due in June 2028). In the first quarter of 2023, we received an upfront payment of $500.0 million when we entered into a royalty purchase agreement with Royalty Pharma and recorded a corresponding long-term liability related to the sale of future
royalties.
The following table summarizes our contractual obligations, excluding our liability related to the sale of future royalties, as of September 30, 2023. The table provides a breakdown of when obligations become due. We provide a more detailed description of the major components of our debt in the paragraphs following the
table:
Contractual Obligations
|
Payments Due by Period (in millions)
|
||||||||||||
|
(selected balances described below)
|
Total
|
Less than 1 year
|
More than 1 year
|
|||||||||
|
1.75% Notes (principal and interest payable)
|
$
|
625.4
|
$
|
10.1
|
$
|
615.3
|
||||||
|
0% Notes (principal payable)
|
632.5
|
—
|
632.5
|
|||||||||
|
0.125% Notes (principal and interest payable)
|
44.7
|
0.1
|
44.6
|
|||||||||
|
Operating leases
|
284.6
|
20.3
|
264.3
|
|||||||||
|
Building mortgage payments (principal and interest payable)
|
10.3
|
0.5
|
9.8
|
|||||||||
|
Other obligations (principal and interest payable)
|
0.8
|
0.1
|
0.7
|
|||||||||
|
Total
|
$
|
1,598.3
|
$
|
31.1
|
$
|
1,567.2
|
||||||
Our contractual obligations consist primarily of our convertible debt. In addition, we also have facility leases, a facility mortgage,
equipment financing arrangements and other obligations. We have not entered into, nor do we currently have, any off-balance sheet arrangements (as defined
under SEC rules).
Convertible Debt and Call Spread
Refer to Part I, Item 1, Note 12, Convertible
Debt, in the Notes to our condensed consolidated financial statements for the significant terms of each convertible debt instrument.
Operating Facilities
In July 2017, we purchased the building that houses our primary R&D facility for $79.4 million and our manufacturing facility for
$14.0 million. We financed the purchase of these two facilities with mortgage debt of $60.4 million in total. Our manufacturing facility mortgage, which has an interest rate of 4.20 percent, matures in August 2027.
In October 2022, we concurrently entered into two purchase and sale agreements with a real estate investor. In the same month, we closed
the first transaction in which we sold and leased back the facilities at our headquarters, which includes our primary R&D facility, for a purchase price of $263.4 million. We used a portion of the sale proceeds from our primary R&D facility to
extinguish our mortgage debt on the facility of $51.3 million. In August 2023, we closed the second transaction and transferred legal ownership of two lots of undeveloped land adjacent to our headquarters to the real estate investor for a purchase
price of $33 million. In connection with this transaction, we entered into a build-to-suit lease agreement with the same real estate investor to lease a new R&D facility.
In October 2022, we entered into a build-to-suit lease agreement to lease a development chemistry and manufacturing facility in Oceanside,
California. In August 2023, we reached a mutual agreement with the lessor to terminate the lease agreement. We do not believe the termination of the lease impacts our ability to successfully commercialize our medicines. Refer to Part I, Item 1, Note
13, Real Estate Transactions, in the Notes to our condensed consolidated financial statements for further details on these agreements.
Operating Leases
Refer to our Leases accounting policy in Part IV, Item 15, Note 4, Long-Term Obligations and Commitments, of our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 for further details on our operating leases.
Liability Related to Sale of Future Royalties
Refer to Part I, Item 1, Note 11, Liability Related to Sale of Future Royalties, in the Notes to our condensed consolidated financial statements for further details on our royalty purchase agreement with Royalty Pharma.
Other Obligations
In addition to contractual obligations, we had outstanding purchase orders as of September 30, 2023 for the purchase of services, capital equipment and materials as part of our
normal course of business.
We may enter into additional collaborations with partners which could provide for additional revenue to us and we may incur additional
cash expenditures related to our obligations under any of the new agreements we may enter into. We currently intend to use our cash, cash equivalents and short-term investments to finance our activities. However, we may also pursue other financing
alternatives, like issuing additional shares of our common stock, issuing debt instruments, refinancing our existing debt, or securing lines of credit. Whether we use our existing capital resources or choose to obtain financing will depend on various
factors, including the future success of our business, the prevailing interest rate environment and the condition of financial markets generally.
We are exposed to changes in interest rates primarily from our investments in certain short-term investments. We primarily
invest our excess cash in highly liquid short-term investments of the U.S. Treasury and reputable financial institutions, corporations, and U.S. government agencies with strong credit ratings. We typically hold our investments for the duration of the
term of the respective instrument. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions to manage exposure to interest rate changes. Accordingly, we
believe that, while the securities we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity
prices, equity prices or other market changes that affect market risk sensitive instruments.
We are also exposed to changes in foreign currency exchange rates as we have foreign subsidiaries with functional
currencies other than the U.S. dollar. We translate our subsidiaries’ functional currencies into our reporting currency, the U.S. dollar. As a result, our financial position, results of operations and cash flows can be affected by market fluctuations
in the foreign currencies to U.S. dollar exchange rate, which are difficult to predict. A hypothetical 10 percent change in foreign exchange rates during any of the periods presented would not have had a material impact on our condensed consolidated
financial statements.
| ITEM 4. |
CONTROLS AND PROCEDURES
|
We maintain disclosure controls and procedures that are designed to ensure that information we are required to disclose in
our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer
and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We design and evaluate our disclosure controls and procedures recognizing that any controls and procedures, no matter how well designed and operated,
can provide only reasonable assurance and not absolute assurance of achieving the desired control objectives.
As of our most recently completed fiscal year and as of the end of the period covered by this Quarterly Report on Form
10-Q, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, under the supervision and
with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were
effective as of September 30, 2023. There have been no
significant changes in our internal controls or in other factors that could significantly affect internal controls subsequent to September 30, 2023.
We also performed an evaluation of any changes in our internal controls over financial reporting that occurred
during our last fiscal quarter and that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. We conducted this evaluation under the supervision of and with the participation of our
management, including our Chief Executive Officer and Chief Financial Officer. That evaluation did not identify any changes in our internal controls over financial reporting that occurred during our latest fiscal quarter and that have materially
affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
| ITEM 1. |
LEGAL PROCEEDINGS
|
For details of legal proceedings, refer to Part I, Item 1, Note 14, Legal Proceedings, in the Notes to our condensed consolidated financial statements.
| ITEM 1A. |
RISK FACTORS
|
Investing in our securities involves a high degree of risk. You should carefully consider the
following information about the risks described below, together with the other information contained in this report and in our other public filings in evaluating our business. If any of the following risks actually occur, our business could be
materially harmed, and our financial condition and results of operations could be materially and adversely affected. As a result, the trading price of our securities could decline, and you might lose all or part of your investment. We have marked with
an asterisk those risk factors that reflect substantive changes from the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2022.
Summary of Risk Factors
There are a number of risks related to our business and our securities. Some of the principal risks related to our
business include the following:
| ● |
Our ability to generate substantial revenue from the sale of our medicines;
|
| ● |
Τhe availability of adequate coverage and payment rates for our
medicines;
|
| ● |
Our and our partners’ ability to compete effectively;
|
| ● |
Our ability to successfully manufacture our medicines;
|
| ● |
Our ability to successfully develop and obtain marketing approvals for our medicines;
|
| ● |
Our ability to secure and maintain effective corporate partnerships;
|
| ● |
Our ability to sustain cash flows and achieve consistent profitability;
|
| ● |
Our ability to protect our intellectual property;
|
| ● |
Our ability to maintain the effectiveness of our personnel;
|
| ● |
The impacts of the COVID-19 pandemic and ongoing wars between Russia/Ukraine and Israel/Hamas; and
|
| ● |
The other factors set forth below.
|
Risks Related to the Commercialization of our Medicines
We have limited experience as a company in commercializing medicines and we will have to invest significant resources to develop our
capabilities. If we are unable to establish effective marketing, sales, market access, distribution, and related functions, or enter into agreements with third parties to commercialize our medicines, we may not be able to generate revenue from our
medicines.
We currently rely on third parties for the commercialization of our marketed medicines, have limited experience as a
company in commercializing medicines and will have to invest significant financial and management resources to develop the infrastructure required to successfully commercialize our medicines. There are significant risks involved in building and
managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed
sales and marketing team. We will also need to scale-up existing internal support functions to aid our commercialization efforts, in particular, regulatory affairs and medical affairs. Any failure to effectively build or maintain the infrastructure
required to successfully commercialize our medicines, including our sales, marketing, market access, distribution, and related capabilities, or scale-up our existing support functions, could adversely impact the revenue we generate from our
medicines. In addition, if we choose to rely on third parties to assist us in commercializing our medicines, we may not be able to enter into collaborations or hire consultants or external service providers on acceptable financial terms, or at all.
If we continue to engage third parties to assist us in the commercialization of our medicines, our product revenues and profitability may be lower than if we commercialized such medicines ourselves.
If the market does not accept our medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen, and our other
medicines in development, we are not likely to generate substantial revenues or become consistently profitable.
Even if our medicines are authorized for marketing, our success will depend upon the medical community, patients and
third-party payers accepting our medicines as medically useful, cost-effective, safe and convenient. Even when the FDA or foreign regulatory authorities authorize our or our partners’ medicines for commercialization, doctors may not prescribe our
medicines to treat patients. Furthermore, we and our partners may not successfully commercialize additional medicines.
Additionally, in many of the markets where we
or our partners may sell our medicines in the future, if we or our partners cannot agree with the government or other third-party payers regarding the price we can charge for our medicines, we may not be able to sell our medicines in that market.
Similarly, cost control initiatives by governments or third-party payers could decrease the price received for our medicines or increase patient coinsurance to a level that makes our medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and
eplontersen, and our medicines in development, economically unviable. If the pricing of any of our medicines decreases for any reason, it will reduce our revenue for such medicine. For example, Biogen has in the past disclosed that SPINRAZA
revenue decreased in part due to lower pricing in the U.S. and certain rest-of-world markets.
The degree of market acceptance for our medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen, and our
medicines in development, depends upon a number of factors, including the:
| ● |
receipt and scope of marketing authorizations;
|
| ● |
establishment and demonstration in the medical and patient community of the efficacy and safety of our medicines and their potential advantages over
competing products;
|
| ● |
cost and effectiveness of our medicines compared to other available therapies;
|
| ● |
patient convenience of the dosing regimen for our medicines; and
|
| ● |
reimbursement policies of government and third-party payers.
|
Based on the profile of our medicines, physicians, patients, patient advocates, payers or the medical community in general
may not accept or use any of the medicines that we may develop.
For example, TEGSEDI requires periodic blood and urine monitoring and is available in the U.S. only through a risk
evaluation and mitigation strategy (“REMS”) program. In addition, the product label for TEGSEDI in the U.S. has a boxed warning for thrombocytopenia and glomerulonephritis. Our main competitors in the U.S. market for TEGSEDI are patisiran and
vutrisiran, both marketed by Alnylam Pharmaceuticals, Inc. Neither patisiran nor vutrisiran has a boxed warning nor does either require use of a REMS program. Additionally, the product label for WAYLIVRA in the European Union, or EU, requires regular
blood monitoring. In each case, these label requirements have negatively affected our ability to attract and retain patients for these medicines. If we or our partner cannot effectively maintain patients on TEGSEDI or WAYLIVRA, including due to
limitations or restrictions on the ability to conduct periodic blood and urine monitoring of our patients as a result of the COVID-19 pandemic, we may not be able to generate substantial revenue from TEGSEDI or WAYLIVRA sales.
If government or other third-party payers fail to provide
adequate coverage and payment rates for our medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen, and our medicines in development, our revenue will be
limited.*
In both domestic and foreign markets, sales of our current and future products will depend in part upon the availability of coverage and
reimbursement from third-party payers. The majority of patients in the U.S. who would fit within our target patient populations for our medicines have their healthcare supported by a combination of Medicare coverage, other government health programs
such as Medicaid, managed care providers, private health insurers and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new medicines when more established or lower cost therapeutic alternatives are
already available or subsequently become available. Assuming coverage is approved, the resulting reimbursement payment rates might not be enough to make our medicines affordable. Even if favorable coverage status and adequate reimbursement rates are
attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Accordingly, QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA
and eplontersen, and our medicines in development, will face competition from other therapies and medicines for limited financial resources. We or our partners may need to conduct post-marketing studies to demonstrate the cost-effectiveness of any
future products to satisfy third-party payers. These studies might require us to commit a significant amount of management time and financial and other resources. In addition, third-party payers may never consider our future products as cost-effective
and adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.
Third-party payers, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated
methods of controlling healthcare costs. In addition, in the U.S., no uniform policy of coverage and reimbursement for medicines exists among third-party payers. Therefore, coverage and reimbursement for medicines can differ significantly from payer to
payer. For example, the Affordable Care Act, or ACA, was passed in March 2010, and substantially changed the way healthcare is financed by both governmental and private insurers and continues to significantly impact the U.S. pharmaceutical industry.
There have been judicial and Congressional challenges to certain aspects of the ACA, as well as efforts to repeal or replace certain aspects of the ACA. It is unclear how future litigation and healthcare reform measures will impact the ACA and our
business.
Further, we believe that future coverage, reimbursement and pricing will likely be subject to increased restrictions both
in the U.S. and in international markets. In the U.S., recent health reform measures have resulted in reductions in Medicare and other healthcare funding, and there have been several recent U.S. Congressional inquiries, legislation and executive orders
designed to, among other things, reduce drug prices, increase competition (including by enhancing support for generic and biosimilar drugs), lower out-of-pocket drug costs for patients, curtail spread pricing practices by pharmacy benefit managers, and
foster scientific innovation to promote better health care and improved health. In addition, the Inflation Reduction Act of 2022, or the IRA, among other things, allows the U.S. Department of Health and Human Services, or HHS, to negotiate the price of
certain single-source drugs covered under Medicare and imposes rebates under Medicare Part B and Medicare Part D. In an effort to curb Medicare patients’ out-of-pocket costs for prescription drugs, the Part D redesign legislation requires manufacturers
to contribute to the catastrophic coverage phase for Part D drugs as discounts through a manufacturer discount program. Furthermore, any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in
payments from private payers. Our future product sales may be subject to additional discounts from list price in the form of rebates and discounts provided to covered entities under the Public Health Service Act 340B drug pricing program. Changes to
the 340B program or to Medicare or Medicaid programs at the federal or state level, including outcomes of ongoing litigation in our industry, may impact our product prices and rebate liability. Further, in February 2023, in response to President
Biden’s executive order released in October 2022, the Secretary of the U.S. Department of HHS selected three new models for testing by the Centers for Medicare & Medicaid Services Innovation Center to help lower the high cost of drugs, promote
accessibility to life-changing drug therapies and improve quality of care. It is unclear whether or how these selected models or similar policy initiatives will impact prescription drug pricing in the future.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing. Third-party coverage and reimbursement for medicines may not be available or adequate in either the U.S. or international markets, which would negatively affect the potential commercial success of
our products, our revenue and our profits.
If we or our partners fail to compete effectively, our medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and
eplontersen, and our medicines in development, will not generate significant revenues.
Our competitors engage in drug discovery throughout the world, are numerous, and include, among others, major
pharmaceutical companies and specialized biopharmaceutical firms. In addition, other companies are engaged in developing RNA-targeted technology. Our competitors may succeed in developing medicines that are:
| ● |
priced lower than our medicines;
|
| ● |
reimbursed more favorably by government and other third-party payers than our medicines;
|
| ● |
safer than our medicines;
|
| ● |
more effective than our medicines; or
|
| ● |
more convenient to use than our medicines.
|
These competitive developments could make our medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen,
and our medicines in development, obsolete or non-competitive.
Certain of our partners are pursuing other technologies or developing other medicines either on their own or in
collaboration with others, including our competitors, to treat some of the same diseases our own collaborative programs target. Competition may negatively impact a partner’s focus on and commitment to our medicines and, as a result, could delay or
otherwise negatively affect the commercialization of our medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen, and our other medicines in development.
Many of our competitors have substantially greater financial, technical and human resources than we do. In addition, many
of these competitors have significantly greater experience than we do in conducting preclinical testing and human clinical studies of new pharmaceutical products, in obtaining FDA and other regulatory authorizations of such products and in
commercializing such products. Accordingly, our competitors may succeed in obtaining regulatory authorization for products earlier than we do or more successfully commercialize their products.
There are several pharmaceutical and biotechnology companies engaged in the development or commercialization in certain
geographic markets of products against targets that are also targets of products in our development pipeline. For example:
| ● |
Onasemnogene abeparvovec and risdiplam compete with SPINRAZA;
|
| ● |
Patisiran, tafamidis, tafamidis meglumine and vutrisiran compete with TEGSEDI and could compete with eplontersen;
|
| ● |
Acoramidis could compete with TEGSEDI and eplontersen;
|
| ● |
ARO-APOC3, lomitapide and pegozafermin could compete with WAYLIVRA and olezarsen;
|
| ● |
Lanadelumab-flyo, C1 esterase inhibitor, berotralstat, C1 esterase inhibitor subcutaneous, garadacimab, and NTLA-2002 could compete with donidalorsen;
|
| ● |
Olpasiran and SLN360 could compete with pelacarsen; and
|
| ● |
NI-204 could compete with QALSODY.
|
SPINRAZA injection for intrathecal use is an antisense medicine indicated for the treatment of SMA patients of all ages approved in over
50 countries. Specifically, SPINRAZA faces competition from onasemnogene abeparvovec, a gene therapy product that was approved in the U.S. in May 2019 and in the EU in May 2020 for the treatment of SMA, as well as risdiplam, an oral product for the
treatment of SMA that was approved in the U.S. in August 2020 and in the EU in March 2021. Biogen has in the past disclosed that SPINRAZA revenue decreased due to a reduction in demand as a result of increased competition and that future sales of
SPINRAZA may be adversely affected by competing products.
Additionally, companies that are developing medicines that target the same patient populations as our medicines in development may compete
with us to enroll participants in the clinical trials for such medicines, which could make it more difficult for us to complete enrollment for these clinical trials.
Our medicines could be subject to regulatory limitations following approval.
Following approval of a medicine, we and our partners must comply with comprehensive government regulations regarding the
manufacture, marketing and distribution of medicines. Promotional communications regarding prescription medicines must be consistent with the information in the product’s approved labeling. We or our partners may not obtain the labeling claims
necessary or desirable to successfully commercialize our medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen, and our medicines in development.
The FDA and foreign regulatory bodies have the authority to impose significant restrictions on an approved medicine
through the product label and on advertising, promotional and distribution activities. For example:
| ● |
in the U.S., TEGSEDI’s label contains a boxed warning for thrombocytopenia and glomerulonephritis;
|
| ● |
TEGSEDI requires periodic blood and urine monitoring; and
|
| ● |
in the U.S., TEGSEDI is available only through a REMS program.
|
Prescription medicines may be promoted only for the approved indication(s) in accordance with the approved label. The
FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.
In addition, when approved, the FDA or a foreign regulatory authority may condition approval on the performance of
post-approval clinical studies or patient monitoring, which could be time consuming and expensive. For example, in connection with the conditional marketing approval for WAYLIVRA in the EU, we are required to conduct a post-authorization safety study
to evaluate the safety of WAYLIVRA on thrombocytopenia and bleeding in FCS patients taking WAYLIVRA. If the results of such post-marketing studies are not satisfactory, the FDA, EC or other foreign regulatory authorities may withdraw marketing
authorization or may condition continued marketing on commitments from us or our partners that may be expensive and time consuming to fulfill.
If we or others identify side effects after any of our medicines are on the market, or if manufacturing problems occur
subsequent to regulatory approval, or if we, our manufacturers or our partners fail to comply with regulatory requirements, we or our partners may, among other things, lose regulatory approval and be forced to withdraw products from the market, need to
conduct additional clinical studies, incur restrictions on the marketing, distribution or manufacturing of the product, and/or change the labeling of our medicines.
We depend on our collaborations with Biogen for the development and commercialization of SPINRAZA and QALSODY.*
We have entered into separate collaborative arrangements with Biogen to develop and commercialize SPINRAZA and QALSODY. We
entered into these collaborations primarily to:
| ● |
fund our development activities for SPINRAZA and QALSODY;
|
| ● |
seek and obtain regulatory approvals for SPINRAZA and QALSODY; and
|
| ● |
successfully commercialize SPINRAZA and QALSODY.
|
We are relying on Biogen to obtain additional regulatory approvals for SPINRAZA and QALSODY, generate additional clinical
data for SPINRAZA and QALSODY, manufacture SPINRAZA and QALSODY, successfully launch QALSODY and continue to successfully commercialize SPINRAZA. In general, we cannot control the amount and timing of resources that Biogen devotes to our
collaborations. If Biogen fails to further develop SPINRAZA or QALSODY, obtain additional regulatory approvals for SPINRAZA or QALSODY, manufacture SPINRAZA or QALSODY, successfully launch QALSODY or continue to successfully commercialize SPINRAZA, or
if Biogen’s efforts in any of these respects are ineffective, revenues for SPINRAZA or QALSODY would be negatively affected.
In addition, our collaborations with Biogen may not continue for various reasons. Biogen can terminate our collaborations
at any time. If Biogen stops developing or commercializing SPINRAZA or QALSODY, we would have to seek or spend additional funding, and SPINRAZA’s or QALSODY’s commercialization may be harmed.
We depend on our collaboration with AstraZeneca for the joint development and commercialization of eplontersen.
We have entered into a collaborative arrangement with AstraZeneca to develop and commercialize eplontersen. Under the
terms of the collaboration agreement, we and AstraZeneca will co-develop and co-commercialize eplontersen in the U.S. and AstraZeneca will have the sole right to commercialize eplontersen in all other countries, except for certain Latin American
countries. Prior to co-commercializing eplontersen in the U.S., we will need to negotiate a co-commercialization agreement with AstraZeneca to govern the parties’ performance of co-commercialization, which agreement will include a commercial plan and
budget. As a company we do not have experience with co-commercialization arrangements. We also do not have control over the amount and timing of resources that AstraZeneca devotes to our collaboration, particularly outside of the U.S. If the
co-commercialization arrangement for eplontersen is not successful for any reason, eplontersen may not meet our commercial objectives and our revenues for eplontersen may be limited.
In addition, a Joint Steering Committee, or JSC, having equal membership from us and AstraZeneca, and various
subcommittees oversee and coordinate the development, manufacturing, commercialization and other exploitation activities for eplontersen in the U.S. by mutual agreement. If any subcommittee cannot reach unanimous agreement on any matter within its
respective scope of authority, such matter may be referred to the JSC for resolution. If the JSC cannot come to a mutual agreement on any particular matter, this could delay our ability to develop or commercialize eplontersen.
If we are not successful in expanding our manufacturing capabilities or cannot manufacture our medicines or contract with
a third party to manufacture our medicines at costs that allow us to charge competitive prices to buyers, we cannot market our products profitably.*
To successfully commercialize any of our medicines, we need to optimize and manage large-scale commercial manufacturing
capabilities either on a standalone basis or through a third-party manufacturer. As our drug development and commercial pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. To that end,
in 2022 we entered into a lease agreement (“Lease”) with a lessor to construct a new manufacturing facility in Oceanside, California to expand our manufacturing infrastructure. In August 2023, we reached a mutual agreement with the lessor to terminate
the Lease. While it remains important to expand our manufacturing infrastructure in the future, we believe our current capabilities and those we obtain through third-party manufacturers will support our manufacturing needs while we secure a suitable
alternative for our manufacturing facility. When we do secure a suitable alternative, we will incur substantial expenditures to build the new manufacturing facility and, following its completion, will likely need to hire and train additional staff to
operate the facility. If we are not successful in executing this expansion, it could limit our ability to meet our manufacturing requirements and commercial objectives in the future and we will not realize the value of our investment in the expansion.
In addition, we have limited experience manufacturing pharmaceutical products of the chemical class represented by our
medicines, called oligonucleotides, on a commercial scale for the systemic administration of a medicine. There are a small number of suppliers for certain capital equipment and raw materials that we use to manufacture our medicines, and some of these
suppliers will need to increase their scale of production to meet our projected needs for commercial manufacturing. Further, we must continue to improve our manufacturing processes to allow us to reduce our drug costs. We or our partners may not be
able to manufacture our medicines at a cost or in quantities necessary to make commercially successful products.
Manufacturers, including us, must adhere to the FDA’s cGMP regulations and similar regulations in foreign countries, which
the applicable regulatory authorities enforce through facilities inspection programs. We, our partners and our contract manufacturers may not comply or maintain compliance with cGMP, or similar foreign regulations. Non-compliance could significantly
delay or prevent receipt of marketing authorizations for our medicines, including authorizations for QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen, and our medicines in development, or could result in enforcement action after authorization that
might limit the commercial success of our medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen, and our medicines in development.
We rely on third-party manufacturers to supply the drug substance and drug product for TEGSEDI and drug product for
WAYLIVRA. Any delays or disruption to our own or third-party commercial manufacturing capabilities, including any interruption to our supply chain as a result of the COVID-19 pandemic or the ongoing war between Russia and Ukraine, could limit the
commercial success of our medicines.
We are relying on third parties to market, sell and distribute TEGSEDI and WAYLIVRA.*
We have entered into agreements with third parties to commercialize TEGSEDI and WAYLIVRA as follows:
| ● |
In April 2021, we entered into a distribution agreement with Sobi to commercialize TEGSEDI in the U.S. and Canada. Effective October 24, 2023, such
agreement was terminated;
|
| ● |
In December 2020, we entered into a distribution agreement with Sobi to commercialize TEGSEDI and WAYLIVRA in Europe; and
|
| ● |
In August 2018, we granted PTC the exclusive right to commercialize TEGSEDI and WAYLIVRA in Latin America and certain Caribbean countries.
|
We are relying on Sobi and PTC to effectively market, sell and distribute TEGSEDI and WAYLIVRA and have less control over sales efforts
and may receive less revenue than if we commercialized TEGSEDI or WAYLIVRA by ourselves. If Sobi or PTC does not successfully commercialize TEGSEDI or WAYLIVRA, including as a result of delays or disruption caused by the COVID-19 pandemic, we may
receive limited revenue for TEGSEDI or WAYLIVRA in Europe, Latin America or certain Caribbean countries, which could adversely affect our business, prospects, financial condition and results of operations.
Risks Related to the Development and Regulatory Approval of our Medicines
If we or our partners fail to obtain regulatory approval for our medicines and additional approvals for QALSODY, SPINRAZA,
TEGSEDI and WAYLIVRA, we or our partners cannot sell them in the applicable markets.
We cannot guarantee that any of our medicines will be considered safe and effective or will be approved for
commercialization. In addition, it is possible that QALSODY, SPINRAZA, TEGSEDI and WAYLIVRA may not be approved in additional markets or for additional indications. We and our partners must conduct time-consuming, extensive and costly clinical studies
to demonstrate the safety and efficacy of each of our medicines before they can be approved or receive additional approvals for sale. We and our partners must conduct these studies in compliance with FDA regulations and with comparable regulations in
other countries.
We and our partners may not obtain necessary regulatory approvals on a timely basis, if at all, for our medicines. It is
possible that regulatory agencies will not approve our medicines for marketing or QALSODY, SPINRAZA, TEGSEDI or WAYLIVRA in additional markets or for additional indications. If the FDA or another regulatory agency believes that we or our partners have
not sufficiently demonstrated the safety or efficacy of any of our medicines, including QALSODY, SPINRAZA, TEGSEDI and WAYLIVRA, or our medicines in development, the agency will not approve the specific medicine or will require additional studies,
which could be time consuming and expensive and delay or harm commercialization of the medicine. For example, in August 2018 we received a complete response letter from the FDA regarding the new drug application for WAYLIVRA in which the FDA determined
that the safety concerns identified with WAYLIVRA in our clinical development program outweighed the expected benefits of triglyceride lowering in patients with FCS. We also received a Non-W from Health Canada for WAYLIVRA in November 2018.
The FDA or other comparable foreign regulatory authorities can delay, limit or deny approval of a medicine for many
reasons, including:
| ● |
such authorities may disagree with the design or implementation of our clinical studies;
|
| ● |
we or our partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that a medicine is safe and effective for
any indication;
|
| ● |
such authorities may not accept clinical data from studies conducted at clinical facilities that have deficient clinical practices or that are in
countries where the standard of care is potentially different from the U.S.;
|
| ● |
we or our partners may be unable to demonstrate that our medicine’s clinical and other benefits outweigh its safety risks to support approval;
|
| ● |
such authorities may disagree with the interpretation of data from preclinical or clinical studies;
|
| ● |
such authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers who manufacture clinical and commercial
supplies for our medicines, or may delay the inspection of such facilities due to restrictions related to the COVID-19 pandemic; and
|
| ● |
the approval policies or regulations of such authorities or their prior guidance to us or our partners during clinical development may significantly
change in a manner rendering our clinical data insufficient for approval.
|
Failure to receive marketing authorization for our medicines, or failure to receive additional marketing authorizations
for QALSODY, SPINRAZA, TEGSEDI or WAYLIVRA, or delays in these authorizations, could prevent or delay commercial introduction of the medicine, and, as a result, could negatively impact our ability to generate revenue from product sales.
If the results of clinical testing indicate that any of our medicines are not suitable for commercial use, we may need to
abandon one or more of our drug development programs.
Drug discovery and drug development have inherent risks and the historical failure rate for drugs is high. Antisense
medicines are a relatively new approach to therapeutics. If we cannot demonstrate that our medicines are safe and effective for human use in the intended indication(s), we may need to abandon one or more of our drug development programs.
Even if our medicines are successful in preclinical and human clinical studies, the medicines may not be successful in
late-stage clinical studies.
Successful results in preclinical or initial human clinical studies, including the Phase 2 results for some of our
medicines in development, may not predict the results of subsequent clinical studies. If any of our medicines in Phase 3 clinical studies, including the studies of QALSODY, bepirovirsen, donidalorsen, eplontersen, IONIS-FB-LRx, olezarsen,
pelacarsen, ulefnersen and zilganersen, do not show sufficient efficacy in patients with the targeted indication, or if such studies are discontinued for any other reason, it could negatively impact our development and commercialization goals for these
medicines and our stock price could decline.
In the past, we have invested in clinical studies of medicines that have not met the primary clinical endpoints in their
Phase 3 studies or have been discontinued for other reasons. For example, in October 2021, Biogen reported that QALSODY did not meet the primary clinical endpoint in the Phase 3 VALOR study; however, trends favoring QALSODY were seen across multiple
secondary and exploratory measures of disease activity and clinical function. In addition, in March 2021, Roche decided to discontinue dosing in the Phase 3 GENERATION HD1 study of tominersen in patients with manifest Huntington’s disease based on the
results of a pre-planned review of data from the Phase 3 study conducted by an unblinded Independent Data Monitoring Committee. Similar results could occur in clinical studies for our other medicines, including the studies of QALSODY, bepirovirsen,
donidalorsen, eplontersen, IONIS-FB-LRx, olezarsen, pelacarsen, ulefnersen and zilganersen.
There are a number of factors that could cause a clinical study to fail or be delayed, including:
| ● |
the clinical study may produce negative or inconclusive results;
|
| ● |
regulators may require that we hold, suspend or terminate clinical research for noncompliance with regulatory requirements;
|
| ● |
we, our partners, the FDA or foreign regulatory authorities could suspend or terminate a clinical study due to adverse side effects of a medicine on
subjects or lack of efficacy in the trial;
|
| ● |
we or our partners may decide, or regulators may require us, to conduct additional preclinical testing or clinical studies;
|
| ● |
enrollment in our clinical studies may be slower than we anticipate;
|
| ● |
we or our partners, including our independent clinical investigators, contract research organizations and other third-party service providers on which we
rely, may not identify, recruit and train suitable clinical investigators at a sufficient number of study sites or timely enroll a sufficient number of study subjects in the clinical study;
|
| ● |
the institutional review board for a prospective site might withhold or delay its approval for the study;
|
| ● |
people who enroll in the clinical study may later drop out due to adverse events, a perception they are not benefiting from participating in the study,
fatigue with the clinical study process or personal issues;
|
| ● |
a clinical study site may deviate from the protocol for the study;
|
| ● |
the cost of our clinical studies may be greater than we anticipate;
|
| ● |
our partners may decide not to exercise any existing options to license and conduct additional clinical studies for our medicines; and
|
| ● |
the supply or quality of our medicines or other materials necessary to conduct our clinical studies may be insufficient, inadequate or delayed.
|
The COVID-19 pandemic could make some of these factors more likely to occur.
In addition, our current medicines, including QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen are chemically similar
to each other. As a result, a safety observation we encounter with one of our medicines could have, or be perceived by a regulatory authority to have, an impact on a different medicine we are developing. This could cause the FDA or other regulators to
ask questions or take actions that could harm or delay our ability to develop and commercialize our medicines or increase our costs. For example, the FDA or other regulatory agencies could request, among other things, additional information or
commitments before we can start or continue a clinical study, protocol amendments, increased safety monitoring, additional product labeling information, and post-approval commitments. This happened in connection with the conditional marketing approval
for WAYLIVRA in the EU, as the EC is requiring us to conduct a post-authorization safety study to evaluate the safety of WAYLIVRA on thrombocytopenia and bleeding in FCS patients taking WAYLIVRA. We have ongoing post-marketing studies for WAYLIVRA and
TEGSEDI and an EAP for WAYLIVRA. Adverse events or results from these studies or the EAPs could negatively impact our pending or future marketing approval applications for WAYLIVRA and TEGSEDI in patients with FCS or ATTRv-PN, respectively, or the
commercial opportunity for WAYLIVRA or TEGSEDI.
Any failure or delay in our clinical studies, including the studies of QALSODY, bepirovirsen, donidalorsen, eplontersen,
IONIS-FB-LRx, olezarsen, pelacarsen, ulefnersen and zilganersen, could reduce the commercial potential or viability of our medicines.
We depend on third parties to conduct clinical studies for our medicines and any failure of those parties to fulfill their
obligations could adversely affect our development and commercialization plans.
We depend on independent clinical investigators, contract research organizations and other third-party service providers
to conduct our clinical studies for our medicines and expect to continue to do so in the future. For example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos
Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including donidalorsen, eplontersen, olezarsen, ulefnersen and zilganersen. We rely heavily on these parties for successful execution of our clinical studies,
but do not control many aspects of their activities. For example, the investigators are not our employees, but we are responsible for ensuring that such investigators conduct each of our clinical studies in accordance with the general investigational
plan and approved protocols for the study. Third parties may not complete activities on schedule or may not conduct our clinical studies in accordance with regulatory requirements or our stated protocols. For example, some of our key vendors are
experiencing labor shortages, which could impact their ability to perform services for us for certain of our clinical trials. The failure of these third parties to carry out their obligations, including as a result of delays or disruptions caused by
the COVID-19 pandemic, or a termination of our relationship with such third parties, could delay or prevent the development, marketing authorization and commercialization of our medicines or additional marketing authorizations for TEGSEDI and WAYLIVRA.
In addition, while we do not have any clinical trial sites in Ukraine or Gaza, we do have a limited number of clinical
trial sites in Russia and Israel that may be materially impacted by the ongoing war between Russia and Ukraine and recent war between Israel and Hamas, respectively, and could result in difficulties enrolling or completing our clinical trials in such
areas on schedule. Furthermore, the U.S. and its European allies have imposed significant sanctions against Russia, including regional embargoes, full blocking sanctions, and other restrictions targeting major Russian financial institutions. The U.S.
government has also indicated it will consider imposing additional sanctions and other similar measures in the future. Our ability to conduct clinical trials in Russia may become restricted under applicable sanctions laws, which would require us to
identify alternative trial sites, and could increase our costs and delay the clinical development of certain of our medicines.
Since corporate partnering is a significant part of our strategy to fund the advancement and commercialization of our
development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on our drug development programs.
To date, corporate partnering has played a significant role in our strategy to fund our development programs and to add
key development resources. We plan to continue to rely on additional collaborative arrangements to develop and commercialize some of our unpartnered medicines. However, we may not be able to negotiate favorable collaborative arrangements for these drug
programs. If we cannot continue to secure additional collaborative partners, our revenues could decrease and the development of our medicines could suffer.
Our corporate partners are developing and funding many of the medicines in our development pipeline. For example, we are
relying on:
| ● |
AstraZeneca for the joint development and funding of eplontersen;
|
| ● |
Novartis for development and funding of pelacarsen;
|
| ● |
GSK for development and funding of bepirovirsen; and
|
| ● |
Roche for development and funding of IONIS-FB-LRx.
|
If any of these pharmaceutical companies stops developing and funding these medicines, our business could suffer and we
may not have, or be willing to dedicate, the resources available to develop these medicines on our own. Our collaborators can terminate their relationships with us under certain circumstances, many of which are outside of our control. For example, in
2022, Pfizer and Bayer decided to discontinue the clinical development programs for vupanorsen and fesomersen, respectively.
Even with funding from corporate partners, if our partners do not effectively perform their obligations under our
agreements with them, it would delay or stop the progress of our drug development and commercial programs.
In addition to receiving funding, we enter into collaborative arrangements with third parties to:
| ● |
conduct clinical studies;
|
| ● |
seek and obtain marketing authorizations; and
|
| ● |
manufacture and commercialize our medicines.
|
Once we have secured a collaborative arrangement to further develop and commercialize one of our drug development
programs, such as our collaborations with AstraZeneca, Biogen, GSK, Novartis and Roche, these collaborations may not continue or result in commercialized medicines, or may not progress as quickly as we anticipated.
For example, a collaborator such as AstraZeneca, Biogen, GSK, Novartis or Roche, could determine that it is in its
financial interest to:
| ● |
pursue alternative technologies or develop alternative products that may be competitive with the medicine that is part of the collaboration with us;
|
| ● |
pursue higher-priority programs or change the focus of its own development programs; or
|
| ● |
choose to devote fewer resources to our medicines than it does to its own medicines.
|
If any of these occur, it could affect our partner’s commitment to the collaboration with us and could delay or otherwise
negatively affect the commercialization of our medicines, including QALSODY, SPINRAZA, bepirovirsen, eplontersen, IONIS-FB-LRx and pelacarsen.
We may not be able to benefit from orphan drug designation for our medicines.
In the U.S., under the Orphan Drug Act, the FDA may designate a medicine as an orphan drug if it is
intended to treat a rare disease or condition affecting fewer than 200,000 individuals in the U.S. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process, but it can provide
financial incentives, such as tax advantages and user-fee waivers, as well as longer regulatory exclusivity periods. The FDA has granted orphan drug designation to donidalorsen for the treatment of patients with HAE, to ulefnersen for the treatment of
patients with FUS-ALS, to ION582 for the treatment of patients with Angelman syndrome and to ION356 for the treatment of patients with Pelizaeus-Merzbacher disease. The FDA and EMA have granted orphan drug designation to eplontersen for the treatment
of patients with ATTR, to TEGSEDI for the treatment of patients with ATTRv-PN, to WAYLIVRA for the treatment of patients with FCS, and to tominersen for the treatment of patients with HD. In addition, the EMA has granted orphan drug designation to
WAYLIVRA for the treatment of patients with FPL. Even if approval is obtained on a medicine that has been designated as an orphan drug, we may lose orphan drug exclusivity if the FDA or EMA determines that the request for designation was materially
defective or if we cannot assure sufficient quantity of the applicable medicine to meet the needs of patients with the rare disease or condition, or if a competitor is able to gain approval for the same medicine in a safer or more effective form or
that makes a major contribution to patient care. If we lose orphan drug exclusivity on any of our medicines, we may face increased competition and lose market share for such medicine.
Risks Associated with our Businesses as a Whole
Risks related to our financial condition
If we fail to obtain timely funding, we may need to curtail or abandon some of our programs.
Many of our medicines are undergoing clinical studies or are in the early stages of research and development. Most of our
programs will require significant additional research, development, manufacturing, preclinical and clinical testing, marketing authorizations, preclinical activities and commitment of significant additional resources prior to their successful
commercialization. In addition, as we commercialize more medicines on our own, we will need to invest significant financial resources to continue developing the infrastructure required to successfully commercialize our medicines, including the
build-out of a new manufacturing facility. All of these activities will require significant cash. As of September 30, 2023, we had cash, cash
equivalents and short-term investments equal to $2.2 billion. If we or our partners do not meet our goals to successfully commercialize our
medicines, including QALSODY, SPINRAZA, TEGSEDI and WAYLIVRA, or to license certain medicines and proprietary technologies, we will need additional funding in the future. Our future capital requirements will depend on many factors such as:
| ● |
successful commercialization of QALSODY, SPINRAZA, TEGSEDI and WAYLIVRA;
|
| ● |
the profile and launch timing of our medicines, including bepirovirsen, donidalorsen, eplontersen, IONIS-FB-LRx, olezarsen, pelacarsen,
ulefnersen and zilganersen;
|
| ● |
changes in existing collaborative relationships and our ability to establish and maintain additional collaborative arrangements;
|
| ● |
continued scientific progress in our research, drug discovery and development programs;
|
| ● |
the size of our programs and progress with preclinical and clinical studies;
|
| ● |
the time and costs involved in obtaining marketing authorizations;
|
| ● |
competing technological and market developments, including the introduction by others of new therapies that address our markets; and
|
| ● |
our manufacturing requirements and capacity to fulfill such requirements.
|
If we need additional funds, we may need to raise them through public or private financing. Additional financing may not
be available on acceptable terms or at all. If we raise additional funds by issuing equity securities, the shares of existing stockholders will be diluted and the price, as well as the price of our other securities, may decline. If adequate funds are
not available or not available on acceptable terms, we may have to cut back on one or more of our research, drug discovery or development programs. Alternatively, we may obtain funds through arrangements with collaborative partners or others, which
could require us to give up rights to certain of our technologies or medicines.
We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future.
Because drug discovery and development require substantial lead-time and money prior to commercialization, our expenses
have generally exceeded our revenue since we were founded in January 1989. As of September 30, 2023, we had an accumulated deficit of
approximately $1.8 billion and stockholders’ equity of approximately $0.3 billion. Most of our historical losses resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated
with our operations. Most of our income has historically come from collaborative arrangements, including commercial revenue from royalties and R&D revenue, with additional income from research grants and the sale or licensing of our patents, as
well as interest income. We will now and continuing into the foreseeable future need to invest significant financial resources to develop capabilities to commercialize medicines on our own and expect that our income in the future will be driven
primarily by commercial sales. If we do not earn substantial revenue from commercial sales, we may incur additional operating losses in the future, which could restrict our ability to successfully develop additional medicines or sustain future
profitability.
We may not be entitled to obtain additional milestone payments under our royalty monetization agreement with Royalty
Pharma.
In January 2023, we entered into a Royalty Purchase Agreement with Royalty Pharma Investments. In addition to the $500
million we received at closing, this agreement makes available to us up to an additional $625 million in milestone payments. However, these additional milestone payments are subject to satisfaction of certain conditions related to the regulatory
approval or commercial sales of pelacarsen, in certain cases by specific deadlines. Should we not satisfy such conditions by the applicable deadlines, or if we fail to meet our obligations or default under this agreement, the actual amount of
additional payments to us could be substantially less than the maximum amounts available thereunder.
Risks related to our intellectual property
If we cannot protect our patent rights or our other proprietary rights, others may compete more effectively against us.
Our success depends to a significant degree upon whether we can continue to develop, secure and maintain intellectual
property rights to proprietary products and services. However, we may not receive issued patents on any of our pending patent applications in the U.S. or in other countries and we may not be able to obtain, maintain or enforce our patents and other
intellectual property rights, any of which could impact our ability to compete effectively. In addition, the scope of any of our issued patents may not be sufficiently broad to provide us with a competitive advantage. Furthermore, other parties may
successfully challenge, invalidate or circumvent our issued patents or patents licensed to us so that our patent rights do not create an effective competitive barrier or revenue source.
We cannot be certain that the U.S. Patent and Trademark Office, or U.S. PTO, and courts in the U.S. or the patent offices and courts in
foreign countries will consider the claims in our patents and applications covering QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA and eplontersen, or any of
our medicines in development as patentable. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an
indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products off-label. Although off-label prescriptions may
infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent, even through legal action.
If we or any licensor partner loses or cannot obtain patent protection for QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA or eplontersen, or any of our medicines in development, it could have a material adverse impact on our business.
Intellectual property litigation could be expensive and prevent us from pursuing our programs.
From time to time, we have to defend our intellectual property rights. If we are involved in an intellectual property
dispute, we may need to litigate to defend our rights or assert them against others. Disputes can involve arbitration, litigation or proceedings declared by the U.S. PTO or the International Trade Commission or foreign patent authorities. Even if
resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition,
there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price
of our common stock.
If a third party claims that our medicines or technology infringe its patents or other intellectual property rights, we
may have to discontinue an important product or product line, alter our products and processes, pay license fees or cease certain activities. We may not be able to obtain a license to needed intellectual property on favorable terms, if at all. There
are many patents issued or applied for in the biotechnology industry, and we may not be aware of patents or patent applications held by others that relate to our business. This is especially true since patent applications in the U.S. are filed
confidentially for the first 18 months. Moreover, the validity and breadth of biotechnology patents involve complex legal and factual questions for which important legal issues remain.
Risks related to product liability
We are exposed to potential product liability claims, and insurance against these claims may not be available to us at a
reasonable rate in the future or at all.
Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing, marketing
and sale of therapeutic products, including potential product liability claims related to QALSODY, SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development. We have clinical study insurance coverage and commercial product liability insurance
coverage. However, this insurance coverage may not be adequate to cover claims against us, or be available to us at an acceptable cost, if at all. Regardless of their merit or eventual outcome, product liability claims may result in decreased demand
for our medicines, injury to our reputation, withdrawal of clinical study volunteers and loss of revenues. Thus, whether or not we are insured, a product liability claim or product recall may result in losses that could be material.
Risks related to our personnel
The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult
to run our business and reduce our likelihood of success.
We are dependent on the principal members of our management and scientific staff, and as we move towards commercializing medicines on our
own, we will become increasingly dependent on the principal members of our commercial team. We do not have employment agreements with any of our employees that would prevent them from leaving us. The loss of our management, key scientific or commercial
employees might slow the achievement of important research and development or commercial goals. It is also critical to our success that we recruit and retain qualified scientific personnel to perform research and development work and that we recruit
and retain qualified marketing, sales, market access, distribution, and related personnel to commercialize our medicines. We may not be able to attract and retain skilled and experienced personnel on acceptable terms because of intense competition for
experienced personnel among many pharmaceutical and health care companies, universities and non-profit research institutions. In addition, failure to succeed in clinical studies may make it more challenging to recruit and retain qualified personnel.
Risks related to the COVID-19 pandemic and other events
Our business may be adversely affected by pandemics, climate change, extreme weather events, earthquakes, war, civil or
political unrest, terrorism or other catastrophic events.
Our business could be adversely affected by
health epidemics in regions where we or our partners are commercializing our medicines, have concentrations of clinical trial sites or other business operations, and could cause disruption in the operations of third-party manufacturers and contract
research organizations upon whom we rely. For example, some physician and hospital policies that were put in place as a result of the COVID-19 pandemic restricted in-person access by third parties, which in some cases impacted our commercialization
efforts for TEGSEDI and WAYLIVRA. In addition, in December 2021, Novartis announced that enrollment for the Phase 3 HORIZON study had been delayed due to the COVID-19 pandemic. The COVID-19 pandemic continues to evolve, and while we believe we have not experienced material adverse effects to our business as a result of the COVID-19 pandemic, the ultimate impact of the COVID-19 pandemic or a
similar health epidemic is highly uncertain.
In recent years, extreme weather events and changing weather patterns have become more common. As a result, we are
potentially exposed to varying natural disaster or extreme weather risks such as hurricanes, tornadoes, fires, droughts, floods, or other events that may result from the impact of climate change on the environment. The potential impacts of climate
change may also include increased operating costs associated with additional regulatory requirements and investments in reducing energy, water use and greenhouse gas emissions. In addition, we currently manufacture most of our research and clinical
supplies in a manufacturing facility located in Carlsbad, California. We manufacture the finished drug product for TEGSEDI and WAYLIVRA at third-party contract manufacturers. Biogen manufactures the finished drug product for SPINRAZA and QALSODY. The
facilities and the equipment we, our partners and our contract manufacturers use to research, develop and manufacture our medicines would be costly to replace and could require substantial lead time to repair or replace. Our facilities or those of our
partners or contract manufacturers may be harmed by natural disasters or other events outside our control, such as earthquakes, war, civil or political unrest, deliberate acts of sabotage, terrorism or industrial accidents such as fire and explosion,
whether due to human or equipment error, and if such facilities are affected by a disaster or other event, our development and commercialization efforts would be delayed. Although we possess property damage and business interruption insurance coverage,
this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In addition, our development and commercialization activities could be harmed or delayed by a shutdown
of the U.S. government, including the FDA.
Risks related to cybersecurity
We are dependent on information technology systems, infrastructure and data, which exposes us to data security risks.
We are dependent upon our own and third-party information technology systems, infrastructure and data, including mobile
technologies, to operate our business. The multitude and complexity of our computer systems may make them vulnerable to service interruption or destruction, disruption of data integrity, malicious intrusion, or random attacks. Likewise, data privacy or
security incidents or breaches by employees or others may pose a risk that sensitive data, including our intellectual property, trade secrets or personal information of our employees, patients, customers or other business partners may be exposed to
unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, with third-party phishing and social engineering attacks in particular increasing during the COVID-19 pandemic. In addition, the
number and frequency of cybersecurity events globally may be heightened during times of geopolitical tension or instability between countries, including, for example, the ongoing war between Russia and Ukraine, as a result of which several companies
(not including us) have reported recent cybersecurity events.
Cyber-attacks could include the deployment of harmful malware, denial-of-service, social engineering and other means to
affect service reliability and threaten data confidentiality, integrity and availability. Our business partners face similar risks and any security breach of their systems could adversely affect our security posture. A security breach or privacy
violation that leads to disclosure or modification of or prevents access to patient information, including personally identifiable information or protected health information, could harm our reputation, compel us to comply with federal and state breach
notification laws and foreign law equivalents, subject us to financial penalties and mandatory and costly corrective action, require us to verify the correctness of database contents and otherwise subject us to litigation or other liability under laws
and regulations that protect personal data, any of which could disrupt our business and result in increased costs or loss of revenue. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security
breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have invested, and continue to invest, in the protection of our data and information technology infrastructure, our efforts may
not prevent service interruptions or identify breaches in our systems that could adversely affect our business and operations and result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational
harm to us.
Risks related to our securities and the global credit markets
If we do not progress in our programs as anticipated, the price of our securities could decrease.
For planning purposes, we estimate and may disclose the timing of a variety of clinical, regulatory and other milestones,
such as when we anticipate a certain medicine will enter clinical trials, when we anticipate completing a clinical study, or when we anticipate filing an application for, or obtaining, marketing authorization, or when we or our partners plan to
commercially launch a medicine. We base our estimates on present facts and a variety of assumptions, many of which are outside of our control, including the impacts of the COVID-19 pandemic. If we do not achieve milestones in accordance with our or our
investors’ or securities analysts’ expectations, including milestones related to QALSODY, SPINRAZA, TEGSEDI, WAYLIVRA, bepirovirsen, donidalorsen, eplontersen, IONIS-FB-LRx, olezarsen, pelacarsen, ulefnersen and zilganersen, the price of our
securities could decrease.
If the price of our securities continues to be highly volatile, this could make it harder to liquidate your investment and
could increase your risk of suffering a loss.
The market price of our common stock, like that of the securities of many other biopharmaceutical companies, has been and
is likely to continue to be highly volatile. These fluctuations in our common stock price may significantly affect the trading price of our securities. During the 12 months preceding September 30, 2023, the market price of our common stock ranged from $47.74 to $32.69 per share. Many factors can affect the market price of our securities, including, for example, fluctuations in our operating results, announcements
of collaborations, clinical study results, technological innovations or new products being developed by us or our competitors, the commercial success of our approved medicines, governmental regulation, marketing authorizations, changes in payers’
reimbursement policies, developments in patent or other proprietary rights and public concern regarding the safety of our medicines.
Broad market factors may materially harm the market price of our common stock irrespective of our operating performance.
For example, the COVID-19 pandemic, the ongoing war between Russia and Ukraine and measures taken in response thereto, the recent war between Israel and Hamas and the failure of Silicon Valley Bank have caused disruptions of global financial markets
and resulted in increased volatility in the trading price of our common stock. In addition, industry factors may materially harm the market price of our common stock. Nasdaq, and the market for biotechnology companies in particular, have historically
experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of ours, may not be
predictable. A loss of investor confidence in the market for biotechnology or pharmaceutical stocks or the stocks of other companies that investors perceive to be similar to us, the opportunities in the biotechnology and pharmaceutical market or the
stock market in general, could depress our stock price regardless of our business, prospects, financial conditions or results of operations.
Provisions in our certificate of incorporation, convertible notes documents, call spread hedge transaction documents and
Delaware law may prevent stockholders from receiving a premium for their shares.*
Our certificate of incorporation provides for classified terms for the members of our board of directors. Our certificate
also includes a provision that requires at least 66 2/3 percent of our voting stockholders to approve a merger or certain other business transactions with, or proposed by, any holder of 15 percent or more of our voting stock, except in cases where
certain directors approve the transaction or certain minimum price criteria and other procedural requirements are met.
Our certificate of incorporation also requires that any action required or permitted to be taken by our stockholders must
be taken at a duly called annual or special meeting of stockholders and may not be taken by written consent. In addition, only our board of directors, chairperson of the board or chief executive officer can call special meetings of our stockholders. We
have in the past, and may in the future, implement a stockholders’ rights plan, also called a poison pill, which could make it uneconomical for a third party to acquire our company on a hostile basis. In addition, our board of directors has the
authority to fix the rights and preferences of, and issue shares of preferred stock, which may have the effect of delaying or preventing a change in control of our company without action by our stockholders.
The provisions of our convertible senior notes could make it more difficult or more expensive for a third party to acquire
us. Upon the occurrence of certain transactions constituting a fundamental change, holders of the notes will have the right, at their option, to require us to repurchase all of their notes or a portion of their notes, which may discourage certain types
of transactions in which our stockholders might otherwise receive a premium for their shares over the then-current market prices.
In June 2023, we completed a $575 million
offering of 1.75% Notes and used a portion of the net proceeds from the issuance of the 1.75% Notes to repurchase $434.1 million of our 0.125% Notes for $420.4 million. In the third quarter of 2023, we repurchased an additional $70.3 million of our
0.125% Notes for $67.8 million. In April 2021, we completed a $632.5 million offering of 0% Notes and used a portion of the net proceeds from the issuance of the 0% Notes to repurchase $247.9 million of our 1% Notes for $257.0 million. In December 2019, we entered into privately negotiated exchange and/or subscription agreements with certain new investors and certain holders of our existing 1% Notes to exchange
$375.6 million of our 1% Notes for $439.3 million of our 0.125% Notes, and to issue $109.5 million of our 0.125% Notes. Additionally, in connection with the pricing of our 0% Notes and 0.125% Notes, we entered into call spread transactions in which
we purchased note hedges and sold warrants. Terminating or unwinding the call spread transactions could require us to make substantial payments to
the counterparties under those agreements or may increase our stock price. The costs or any increase in stock price that may arise from terminating or unwinding such agreements could make an acquisition of our company significantly more expensive to
the purchaser.
These provisions, as well as Delaware law, including Section 203 of the Delaware General Corporation Law, and other of our
agreements, may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over then-current market prices, and may limit the ability of our stockholders to approve transactions that they think
may be in their best interests.
Future sales of our common stock in the public market could adversely affect the trading price of our securities.
Future sales of substantial amounts of our common stock in the public market, or the perception that such sales could
occur, could adversely affect trading prices of our securities. For example, we may issue approximately 22.2 million shares of our common stock upon conversion of our 1.75% Notes, 0% Notes and 0.125% Notes, up to 10.9 million shares in connection with
the warrant transactions we entered into in connection with the issuance of our 0% Notes, and up to 6.6 million shares in connection with the warrant transactions we entered into in connection with the issuance of our 0.125% Notes, in each case subject
to customary anti-dilution adjustments. The addition of any of these shares into the public market may have an adverse effect on the price of our securities.
In addition, pursuant to the call spread transactions we entered into in connection with the pricing of our 0% Notes and
0.125% Notes, the counterparties are likely to modify their hedge positions from time to time at or prior to the conversion or maturity of the notes by purchasing and selling shares of our common stock, other of our securities, or other instruments,
including over-the-counter derivative instruments, that they may wish to use in connection with such hedging, which may have a negative effect on the conversion value of those notes and an adverse impact on the trading price of our common stock. The
call spread transactions are expected generally to reduce potential dilution to holders of our common stock upon any conversion of our 0% Notes or 0.125% Notes or offset any cash payments we are required to make in excess of the principal amount of the
converted 0% Notes or 0.125% Notes, as the case may be. However, the warrant transactions could separately have a dilutive effect to the extent that the market value per share of our common stock exceeds the applicable strike price of the warrants.
Negative conditions in the global credit markets and financial services and other industries may adversely affect our
business, financial condition or stock price.*
The global credit and financial markets have
experienced extreme volatility and disruptions recently, including as a result of the ongoing COVID-19 pandemic, war between Russia and Ukraine and
measures taken in response thereto, and the failure of Silicon Valley Bank. The recent war between Israel and Hamas may also create volatility and disruptions in the global credit markets. These disruptions can result in severely diminished liquidity
and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and
confidence in economic conditions will not occur. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a
timely manner and on favorable terms could have a material adverse effect on our operations, growth plans, financial performance or stock price. In addition, our insurance carriers and insurance policies covering all aspects of our business may
become financially unstable or may not be sufficient to cover any or all of our losses and may not continue to be available to us on acceptable terms, or at all. Furthermore, due to the rapidly rising inflation rate, we may experience significantly
increased costs of goods and services for our business.
A variety of risks associated with operating our business and marketing our medicines internationally could adversely affect our business.
In addition to our U.S. operations, we are commercializing TEGSEDI in the EU, Canada, Latin America and certain Caribbean countries, and WAYLIVRA in the EU, Latin America and certain Caribbean countries. We face risks associated with our international
operations, including possible unfavorable regulatory, pricing and reimbursement, political, tax and labor conditions, which could harm our business. Because we have international operations, we are subject to numerous risks associated with
international business activities, including:
| ● |
compliance with differing or unexpected regulatory requirements for our medicines and foreign employees;
|
| ● |
complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems;
|
| ● |
difficulties in staffing and managing foreign operations;
|
| ● |
in certain circumstances, increased dependence on the commercialization efforts and regulatory compliance of third-party distributors or strategic
partners;
|
| ● |
foreign government taxes, regulations and permit requirements;
|
| ● |
U.S. and foreign government tariffs, trade restrictions, price and exchange controls and other regulatory requirements;
|
| ● |
anti-corruption laws, including the Foreign Corrupt Practices Act, or the FCPA, and its equivalent in foreign jurisdictions;
|
| ● |
economic weakness, including inflation, natural disasters, war, events of terrorism, political instability or public health issues or pandemics, such as
the COVID-19 pandemic, in particular foreign countries or globally;
|
| ● |
fluctuations in currency exchange rates, which could result in increased operating expenses and reduced revenue, and other obligations related to doing
business in another country;
|
| ● |
compliance with tax, employment, privacy, immigration and labor laws, regulations and restrictions for employees living or traveling abroad;
|
| ● |
workforce uncertainty in countries where labor unrest is more common than in the U.S.; and
|
| ● |
changes in diplomatic and trade relationships.
|
Our business activities outside of the U.S. are subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules
of other countries in which we operate, including the United Kingdom’s Bribery Act 2010. In many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are
government entities; therefore, any dealings with these prescribers and purchasers may be subject to regulation under the FCPA. There is no certainty that all employees and third-party business partners (including our distributors, wholesalers, agents,
contractors and other partners) will comply with anti-bribery laws. In particular, we do not control the actions of manufacturers and other third-party agents, although we may be liable for their actions. Violation of these laws may result in civil or
criminal sanctions, which could include monetary fines, criminal penalties, and disgorgement of past profits, which could have an adverse impact on our business and financial condition.
Risks related to compliance with laws
Our operations are subject to additional healthcare laws.
Our operations are subject to additional healthcare laws, including federal and state anti-kickback laws, false claims laws, transparency
laws, such as the federal Sunshine Act, and health information privacy and security laws, which are subject to change at any time. It is possible that governmental authorities will conclude that our business practices may not comply with current or
future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. Penalties for violations of applicable healthcare laws and regulations may include significant civil, criminal and administrative
penalties, damages, disgorgement, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and additional reporting requirements and oversight if we enter into a corporate integrity agreement
or similar agreement to resolve allegations of non-compliance with these laws. In addition, violations may also result in reputational harm, diminished profits and future earnings.
Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with
laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well
as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store most of these materials and various wastes resulting from their use at our facilities in Carlsbad, California
pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause:
| ● |
interruption of our research, development and manufacturing efforts;
|
| ● |
injury to our employees and others;
|
| ● |
environmental damage resulting in costly clean up; and
|
| ● |
liabilities under federal, state and local laws and regulations governing health and human safety, as well as the use, storage, handling and disposal of
these materials and resultant waste products.
|
In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although
we carry insurance for pollution liability in amounts and types that we consider commercially reasonable, the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial
condition would be adversely affected.
Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our
costs and the risk of noncompliance.
Each year we are required to evaluate our internal control systems to allow management to report on and our Independent
Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management’s time to comply with these regulations. In
addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board, or PCAOB, or
The Nasdaq Global Select Market. Any such action could adversely affect our financial results and the market price of our common stock.
The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing
regulations that require our compliance. In July 2010, the Dodd-Frank Wall Street Reform and Protection Act, or the Dodd-Frank Act, was enacted, and in August 2022, the SEC adopted additional rules and regulations under the Dodd-Frank Act related to
“say on pay” and proxy access. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which has and may in
the future lead to additional compliance costs and impact the manner in which we operate our business.
Risks related to taxes
Our ability to use our net operating loss carryovers and certain other tax attributes may be limited.
Under the Internal Revenue Code of 1986, as amended, or the Code, a corporation is generally allowed a deduction for net operating losses,
or NOLs, carried over from a prior taxable year. Under the Code, we can carry forward our NOLs to offset our future taxable income, if any, until such NOLs are used or expire. The same is true of other unused tax attributes, such as tax credits.
Under the current U.S. federal income tax law, U.S. federal NOLs generated in taxable years beginning after December 31, 2017 may be
carried forward indefinitely, but the deductibility of such U.S. federal NOLs is limited to 80 percent of taxable income. It is uncertain if and to what extent various states will conform to current U.S. federal income tax law, and there may be periods
during which states suspend or otherwise limit the use of NOLs for state income tax purposes.
In addition, under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an “ownership
change,” which is generally defined as a greater than 50 percentage-point cumulative change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax
attributes to offset its post-change income or taxes may be limited. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs
and our ability to use our NOL carryforwards or other tax attributes is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. As a result of the Akcea Merger, we are subject to the separate
return limitation year, or SRLY, rules. Under the SRLY rules, our utilization of Akcea’s pre-merger NOL and tax credit carryforwards is limited to the amount of income that Akcea contributes to our consolidated taxable income. The Akcea pre-merger tax
attributes cannot be used to offset any of the income that Ionis contributes to our consolidated taxable income. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which
could accelerate or permanently increase state taxes owed.
Our future taxable income could be impacted by changes in tax laws, regulations and treaties.
A change in tax laws, treaties or regulations, or their interpretation, of any country in which we operate could
materially affect us.
We could be subject to additional tax liabilities.
We are subject to U.S. federal, state, local and foreign income taxes, sales taxes in the U.S., withholding taxes and transaction taxes in
foreign jurisdictions. Significant judgment is required in evaluating our tax positions and our worldwide provision for taxes. During the ordinary course of business, there are many activities and transactions for which the ultimate tax determination
is uncertain. In addition, our tax obligations and effective tax rates could be adversely affected by changes in the relevant tax, accounting and other laws, regulations, principles and interpretations, including those relating to income tax nexus, by
recognizing tax losses or lower than anticipated earnings in jurisdictions where we have lower statutory rates and higher than anticipated earnings in jurisdictions where we have higher statutory rates, by changes in foreign currency exchange rates, or
by changes in the valuation of our deferred tax assets and liabilities. We may be audited in various jurisdictions, and such jurisdictions may assess additional taxes, sales taxes and value-added taxes against us. Although we believe our tax estimates
are reasonable, the final determination of any tax audits or litigation could be materially different from our historical tax provisions and accruals, which could have a material adverse effect on our operating results or cash flows in the period for
which a determination is made.
| ITEM 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
Not applicable.
| ITEM 3. |
DEFAULT UPON SENIOR SECURITIES
|
Not applicable.
| ITEM 4. |
MINE SAFETY DISCLOSURES
|
Not applicable.
| ITEM 5. |
OTHER INFORMATION
|
Trading Plans
During the quarter ended September 30, 2023, our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.
| * |
Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
|
| ** |
“Non-Rule 10b5-1 trading arrangement” as defined in item 408(c) of Regulation S-K under the Exchange Act.
|
|
Action
|
Date
|
Trading Arrangement
|
Total Shares to Be Sold
|
Expiration Date
|
||||||||
|
Rule 10b5-1*
|
Non-Rule 10b5-1**
|
|||||||||||
|
Brett Monia,
CEO and Board Member
|
Termination
|
July 12, 2023
|
X
|
30,023
|
|
|||||||
|
Brett Monia,
CEO and Board Member
|
Adoption
|
July 13, 2023
|
X
|
54,442
|
|
|||||||
|
Eric Swayze,
EVP, Research
|
Adoption
|
July 13, 2023
|
X
|
85,614
|
|
|||||||
|
Spencer Berthelsen,
Board Member
|
Adoption
|
September 7, 2023
|
X
|
16,000
|
|
|||||||
|
B. Lynne Parshall,
Board Member
|
Adoption
|
September 27, 2023
|
X
|
122,638
|
|
|||||||
ITEM 6. EXHIBITS
| a. |
Exhibits
|
|
Exhibit Number
|
Description of Document
|
|
|
Collaboration and License Agreement by and between the Registrant and Novartis Pharma AG dated as of August 2, 2023. Portions of this exhibit have
been omitted because they are both (i) not material and (ii) the type that the Registrant treats as private or confidential.
|
||
|
Amended and Restated Lease Agreement between the
Registrant and Lots 21 & 22 Owner (DE) LLC dated as of August 21, 2023. Portions of this exhibit have been omitted because they are both (i) not material and (ii) the type that the Registrant treats as private or confidential.
|
||
|
Research, Development, and License Agreement by and among the Registrant, F. Hoffmann-La Roche Ltd., and Hoffmann-La Roche Inc. dated as of September
26, 2023. Portions of this exhibit have been omitted because they are both (i) not material and (ii) the type that the Registrant treats as private or confidential.
|
||
|
Certification by Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as
amended.
|
||
|
Certification by Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as
amended.
|
||
|
32.1*
|
Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
101
|
The following financial statements from the Ionis Pharmaceuticals, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) condensed consolidated balance sheets, (ii) condensed
consolidated statements of operations, (iii) condensed consolidated statements of comprehensive income (loss), (iv) condensed consolidated statements of stockholders’ equity, (v) condensed consolidated statements of cash flows and (vi) notes to
condensed consolidated financial statements (detail tagged).
|
|
|
104
|
Cover Page Interactive Data File (formatted in iXBRL and included in exhibit 101).
|
| * |
This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
|
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
persons on behalf of the Registrant and in the capacities and on the dates indicated.
|
Signatures
|
Title
|
Date
|
||
|
/s/ BRETT P. MONIA
|
Director and Chief Executive Officer
|
|||
|
Brett P. Monia, Ph.D.
|
(Principal executive officer)
|
November 2, 2023
|
||
|
/s/ ELIZABETH L. HOUGEN
|
Executive Vice President, Finance and Chief Financial Officer
|
|||
|
Elizabeth L. Hougen
|
(Principal financial and accounting officer)
|
November 2, 2023
|